mitotane has been researched along with Adrenocortical Carcinoma in 257 studies
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high." | 9.69 | Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. ( Arlt, W; Bancos, I; Basile, V; Baudin, E; Berchialla, P; Berruti, A; Bertherat, J; Beuschlein, F; Bourdeau, I; Bovis, F; Bruzzi, P; Canu, L; Caron, P; Chabre, O; Chortis, V; Cosentini, D; Decoudier, B; Dusek, T; Ettaieb, MH; Fassnacht, M; Fragoso, MCBV; Giordano, R; Grisanti, S; Haak, HR; Hahner, S; Haissaguerre, M; Kastelan, D; Kimpel, O; Kroiss, M; Lacroix, A; Lasolle, H; Libé, R; Loli, P; Luconi, M; Megerle, F; Nölting, S; Perotti, P; Puglisi, S; Quinkler, M; Reimondo, G; Sormani, MP; Stigliano, A; Terzolo, M; Zatelli, MC, 2023) |
| "Central hypothyroidism was described previously in mitotane-treated patients but data on its prevalence and time of occurrence are limited." | 9.41 | Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. ( Bourdeau, I; Caron, P; Godemel, S; Grunenwald, S; Lacroix, A; Le, XK; Mourot, A; Olney, HJ; Poirier, J, 2023) |
| "Mitotane is the only approved drug for treatment of adrenocortical carcinoma." | 9.17 | Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. ( Allolio, B; Baudin, E; Chadarevian, R; Fassnacht, M; Haak, HR; Kerkhofs, TM; Leboulleux, S; Mantero, F; Mueller, HH; Skogseid, B; Terzolo, M, 2013) |
| "The benefit-to-risk ratio of a high-dose strategy at the initiation of mitotane treatment of adrenocortical carcinoma (ACC) remains unknown." | 9.16 | High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. ( Al Ghuzlan, A; Baudin, E; Borget, I; Chanson, P; Deandreis, D; Drouard, L; Leboulleux, S; Mauclère-Denost, S; Paci, A; Schlumberger, M; Tabarin, A; Young, J, 2012) |
| "We designed a single-center retrospective study to assess the QT interval duration and to describe cardio vascular events among patients treated with mitotane for a adrenocortical carcinoma (ACC)." | 9.16 | No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. ( Abbas, H; Bertagna, X; Chaderevian, R; Cohen, A; Dufaitre, G; Ederhy, S; Libé, R, 2012) |
| "Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC)." | 9.12 | Pharmacological profile and effects of mitotane in adrenocortical carcinoma. ( Acco, A; Bach, C; Bonatto, SJR; Corso, CR; de Figueiredo, BC; de Souza, LM, 2021) |
| "Mitotane is the only drug registered specifically for adrenocortical carcinoma." | 9.12 | How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives. ( Ettaieb, MHT; Haak, HR; Kerkhofs, TMA; Steenaard, RV, 2021) |
| "A previous Southwest Oncology Group study demonstrated a 30% response rate with the combination of cisplatin and mitotane in the treatment of patients with metastatic adrenocortical carcinoma." | 9.09 | Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. ( Baker, LH; Balcerzak, SP; Crawford, ED; Lew, D; Miller, GJ; Williamson, SK, 2000) |
| "The use of either mitotane or chemotherapy in the treatment of advanced adrenocortical carcinoma (ACC) has led to scanty and controversial results." | 9.08 | Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. ( Angeli, A; Berruti, A; Dogliotti, L; Pia, A; Terzolo, M, 1998) |
| "The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy." | 8.98 | Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( Liang, J; Liu, Z; Lu, Y; Tang, Y; Zhu, Y; Zou, Z, 2018) |
| "Description of novel findings about the mechanism of action of mitotane and its activity as an adjunctive postoperative measure, or for treatment of advanced adrenocortical carcinoma." | 8.90 | Practical treatment using mitotane for adrenocortical carcinoma. ( Allasino, B; De Francia, S; Terzolo, M; Zaggia, B, 2014) |
| "Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, (o,p'-DDD)] is the only drug approved for the treatment for adrenocortical carcinoma (ACC) and has also been used for various forms of glucocorticoid excess." | 8.87 | Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Kroiss, M; Lutz, WK; Quinkler, M, 2011) |
| "Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied." | 8.31 | Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study. ( Alberti, A; Berruti, A; Cappelli, C; Cosentini, D; Cremaschi, V; Delbarba, A; Facondo, P; Ferlin, A; Grisanti, S; Laganà, M; Pezzaioli, LC, 2023) |
| "Mitotane is a chiral drug used to treat adrenocortical carcinoma, being metabolized to the o,p'-dichlorodiphenyl acetic acid (o,p'-DDA), also a chiral compound." | 8.31 | Two-dimensional chromatography for enantiomeric analysis of mitotane and its metabolite o,p'-DDA in patients with adrenocortical carcinoma indicates enantioselective metabolism. ( Bach de Assis, C; Cavalcante de Figueiredo, B; Cruz Bonk, B; de Almeida Veiga, A; de Toledo Nogueira, B; Lada Degaut Pontes, F; Mera de Souza, L; Regina Rocha Martins, L; Rita Corso, C; Stadler, G, 2023) |
| " A 33-year-old woman who underwent surgery for adrenocortical carcinoma and treated with mitotane was referred for infertility." | 8.12 | Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma. ( Belin, F; Bry-Gauillard, H; Grynberg, M; Massin, N; Renoult-Pierre, P; Sifer, C; Vinolas, C; Young, J, 2022) |
| "Mitotane is the only approved drug for treating adrenocortical carcinoma (ACC)." | 8.12 | Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. ( Abate, A; Berruti, A; Cosentini, D; Fiorentini, C; Grisanti, S; Grosso, E; Hantel, C; Laganà, M; Memo, M; Rossini, E; Scatolini, M; Sigala, S; Tamburello, M; Tiberio, GAM, 2022) |
| "Patients with adrenocortical carcinoma (ACC) are frequently on mitotane therapy for a long time period." | 8.12 | Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. ( Al Ghuzlan, A; Baudin, E; Berruti, A; Cosentini, D; Deschamps, F; Frigerio, M; Gasparotti, R; Grisanti, S; Hadoux, J; Laganà, M; Lamartina, L; Libè, R; Maroldi, R; Pedersini, R; Terzolo, M; Valsecchi, C; Zamparini, M, 2022) |
| "Adjuvant treatment with mitotane and chemotherapy is recommended for paediatric advanced and metastatic adrenocortical carcinoma (ACC)." | 8.12 | Key factors for effective mitotane therapy in children with adrenocortical carcinoma. ( Brecht, I; Frühwald, MC; Kuhlen, M; Kunstreich, M; Lessel, L; Mier, P; Redlich, A; Schewe, DM; Schneider, D; Vorwerk, P, 2022) |
| "Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)." | 8.02 | Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. ( Corssmit, EPM; Cusato, J; D'Avolio, A; Eekhoff, M; Ettaieb, MHT; Feelders, RA; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TMA; Kerstens, MN; Moes, DJAR; Swen, JJ; Timmers, HJLM; van der Straaten, RJHM; van Deun, L; Yin, A, 2021) |
| "Mitotane is used in the treatment of adrenocortical carcinoma (ACC)." | 8.02 | Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients. ( Andreassen, M; Daugaard, G; Krogh, J; Vikner, ME, 2021) |
| "This study presents an in vitro evaluation of the antitumor potential of a chitin-like exopolysaccharide (EPS, produced by Mortierella alpina) on Adrenocortical carcinoma cells (ACC) compared to mitotane, a commercial drug commonly used in ACC treatment, and known for its side effects." | 8.02 | In vitro cytotoxic effect of a chitin-like polysaccharide produced by Mortierella alpina on adrenocortical carcinoma cells H295R, and its use as mitotane adjuvant. ( Bonatto, SJR; de Carvalho, JC; Goyzueta Mamani, LD; Soccol, CR; Tanobe, VAO, 2021) |
| "European and French guidelines for ENSAT stage IV low tumor burden or indolent adrenocortical carcinoma (ACC) recommend a combination of mitotane and locoregional treatments (LRT) as first-line treatment." | 8.02 | Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma. ( Al Ghuzlan, A; Baudin, E; Boilève, A; de Baere, T; Deschamps, F; Faron, M; Hadoux, J; Hescot, S; Lamartina, L; Leboulleux, S; Mathy, E; Roux, C; Tselikas, L, 2021) |
| "Patients with adrenocortical carcinoma (ACC) often fail mitotane treatment and deal with severe toxicity, marking the relevance of predictive parameters for treatment outcome." | 7.96 | The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. ( Creemers, SG; de Herder, WW; Dogan, F; Feelders, RA; Franssen, GJH; Hofland, LJ; van Koetsveld, PM, 2020) |
| "Mitotane is an adrenolytic drug that is used as an adjuvant to treat adrenocortical carcinoma." | 7.96 | Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations. ( Abrahamsson, G; Ahlman, H; Ekerhovd, E; Janson, PO; Jansson, S; Norström, A; Wängberg, B, 2020) |
| "Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20%, and adverse drug effects are frequent." | 7.96 | Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. ( Altieri, B; Basile, V; Berruti, A; Canu, L; Della Casa, S; Fassnacht, M; Fragoso, MCBV; Kircher, S; Kroiss, M; Lacombe, AMF; Landwehr, LS; Megerle, F; Paiva, I; Ronchi, CL; Sbiera, S; Schreiner, J; Terzolo, M; Volante, M; Weigand, I; Zerbini, MCN, 2020) |
| " Mitotane therapy of adrenocortical carcinoma (ACC) has been shown to act through lipid-induced ER-stress." | 7.91 | Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. ( Fassnacht, M; Kendl, S; Kroiss, M; Sbiera, I; Sbiera, S; Weigand, I, 2019) |
| "Mitotane (also termed o,p'‑DDD) is the most effective therapy for advanced adrenocortical carcinoma (ACC)." | 7.91 | Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. ( Amazit, L; Baudin, E; Boulate, G; Hescot, S; Lombes, A; Lombes, M; Naman, A; Paci, A; Pussard, E; Seck, A, 2019) |
| "Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce." | 7.88 | Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. ( Beuschlein, F; Fassnacht, M; Hahner, S; Herrmann, W; Kroiss, M; Megerle, F; Pulzer, A; Quinkler, M; Ronchi, CL; Schloetelburg, W, 2018) |
| " Recent studies have shown that an important component in the mechanism of action of mitotane, the only approved drug for the medical treatment of adrenocortical carcinoma (ACC), is represented by activation of ER stress through inhibition of the SOAT1 enzyme and accumulation of toxic lipids." | 7.88 | The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. ( Benhida, R; Doghman-Bouguerra, M; Lalli, E; Rocchi, S; Ronco, C; Ruggiero, C, 2018) |
| "Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity." | 7.88 | CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. ( Berruti, A; De Francia, S; Germano, A; Perotti, P; Rapa, I; Saba, L; Terzolo, M; Volante, M, 2018) |
| "Mitotane is used for the treatment of adrenocortical carcinoma." | 7.88 | Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients. ( Arshad, U; Fassnacht, M; Frechen, S; Fuhr, U; Hamacher, S; Herterich, S; Kroiss, M; Kurlbaum, M; Megerle, F; Taubert, M, 2018) |
| "In 2007, a retrospective case-control study provided evidence that adjuvant mitotane prolongs recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC)." | 7.85 | Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. ( Arvat, E; Berruti, A; Boscaro, M; Claps, M; Daffara, F; Fassnacht, M; Grisanti, S; Hahner, S; Loli, P; Mannelli, M; Porpiglia, F; Pulzer, A; Terzolo, M; Tiberio, G; Volante, M; Zaggia, B, 2017) |
| " The present in-vitro study shows that AMG 900 inhibits aurora kinases in adrenocortical carcinoma cells." | 7.85 | The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line. ( Andrade, AF; Antonini, SRR; Borges, KS; Marco Antonio, DS; Scrideli, CA; Silveira, VS; Tone, LG; Vasconcelos, EJR, 2017) |
| "Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p'-DDE (dichlorodiphenylethene) and o,p'-DDA (dichlorodiphenylacetate)." | 7.85 | Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. ( Allegra, S; Berruti, A; Carrella, S; Cusato, J; D'Avolio, A; Daffara, FC; De Francia, S; De Martino, F; Di Carlo, F; Ferrero, A; Piccione, FM; Pirro, E; Tampellini, M; Terzolo, M, 2017) |
| "Oral mitotane (o,p'-DDD) is a cornerstone of medical treatment for adrenocortical carcinoma (ACC)." | 7.83 | Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. ( Fassnacht, M; Heinz, W; Kendl, S; Klinker, H; Kroiss, M; Lapa, C; Plonné, D; Ronchi, CL; Sbiera, S; Schirbel, A; Schirmer, D; Zink, M, 2016) |
| "Current treatment guidelines recommend adjuvant mitotane after resection of adrenocortical carcinoma with high-risk features (eg, tumor rupture, positive margins, positive lymph nodes, high grade, elevated mitotic index, and advanced stage)." | 7.83 | Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. ( Duh, QY; Ethun, CG; Fields, RC; Gad, S; Glenn, J; Hatzaras, I; Jin, LX; Keplinger, K; Kiernan, CM; Levine, EA; Maithel, SK; Mansour, JC; Pawlik, TM; Phay, JE; Postlewait, LM; Poultsides, GA; Prescott, JD; Salem, A; Seiser, N; Shenoy, R; Sicklick, JK; Solorzano, CC; Staley, CA; Tran, TB; Votanopoulos, KI; Wang, TS; Weber, SM; Yopp, AC, 2016) |
| "Mitotane has been used for more than 5 decades as therapy for adrenocortical carcinoma (ACC)." | 7.83 | Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature. ( Bourdeau, I; Cohade, C; El Ghorayeb, N; Lacroix, A; Latour, M; Mazzuco, TL; Olney, H; Perrotte, P; Rondeau, G; Sabourin, A, 2016) |
| "Evaluation of patient characteristics and mitotane use in the treatment of adrenocortical carcinoma (ACC) over a 4-year period in Belgium." | 7.83 | Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients. ( Banh, C; Bex, M; Chadarevian, R; Gil, T; Maiter, D; T'Sjoen, G; Vroonen, L, 2016) |
| "Mitotane is the only drug approved for treatment of the orphan disease adrenocortical carcinoma (ACC) and was recently shown to be the first clinically used drug acting through endoplasmic reticulum (ER)-stress induced by toxic lipids." | 7.83 | Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. ( Fassnacht, M; Kendl, S; Kroiss, M; Kurlbaum, M; Sbiera, S, 2016) |
| "Mitotane is the drug of choice in medical treatment of adrenocortical carcinoma." | 7.81 | Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma. ( den Hartigh, J; Derijks, LJ; Ettaieb, H; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TM; Neef, K, 2015) |
| "Mitotane is an adrenolytic and anticortisolic drug used in adrenocortical carcinoma (ACC), Cushing's disease (CD), and ectopic ACTH syndrome." | 7.81 | Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. ( Bachelot, A; Baudin, E; Bernard, V; Bry-Gauillard, H; Chanson, P; Crinière, L; Do Cao, C; Droumaguet, C; Guignat, L; Leboulleux, S; Maiter, D; Pierre, P; Salenave, S; Santulli, P; Schlumberger, M; Touraine, P; Young, J, 2015) |
| "Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high-lipid-containing tissues." | 7.81 | Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. ( Baudin, E; Broutin, S; Cockenpot, F; Guerin, M; Hescot, S; Huby, T; Lombès, M; Paci, A; Seck, A; Young, J, 2015) |
| "Mitotane (o,p'DDD) is the most effective treatment of advanced adrenocortical carcinoma (ACC) but its mechanism of action remains unknown." | 7.80 | The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. ( Al Ghuzlan, A; Baudin, E; Brailly-Tabard, S; Hescot, S; Lombès, M; Paci, A; Seck, A; Slama, A; Trabado, S; Viengchareun, S; Young, J, 2014) |
| "Mitotane is currently employed as adjuvant therapy as well as in the medical treatment of adrenocortical carcinoma (ACC), alone or in combination with chemotherapeutic agents." | 7.80 | Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. ( Benfini, K; Di Pasquale, C; Falletta, S; Feo, C; Gagliano, T; Gentilin, E; Tagliati, F; Tassinari, M; Uberti, ED; Zatelli, MC, 2014) |
| "We herein report a case of marked transient hypercholesterolemia in a man receiving low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma." | 7.80 | Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma. ( Inazu, A; Kawashiri, MA; Mabuchi, H; Nohara, A; Tada, H; Yamagishi, M, 2014) |
| "Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC)." | 7.79 | Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. ( Al Ghuzlan, A; Allolio, B; Ardito, A; Baudin, AE; Berruti, A; Daffara, F; De Francia, S; deVries, JH; Fassnacht, M; Feelders, RA; Haak, HR; Kroiss, M; Leboulleux, S; Perotti, P; Terzolo, M; Volante, M; Zaggia, B, 2013) |
| "Mitotane is a widely used drug in the therapy of adrenocortical carcinoma (ACC)." | 7.79 | Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. ( Doghman, M; Lalli, E, 2013) |
| "In patients with adrenocortical carcinoma (ACC) mitotane activity has been suggested to depend on plasma levels 14 mg/liter or greater and metabolite formation." | 7.77 | Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. ( Allolio, B; Baudin, E; Berruti, A; Chadarevian, R; Daffara, F; den Hartigh, J; Fassnacht, M; Haak, HR; Hermsen, IG; Houterman, S; Leboulleux, S; Schlumberger, M; Terzolo, M, 2011) |
| "We present the case of a female patient with virilising adrenocortical carcinoma treated surgically who conceived during adjuvant treatment with mitotane." | 7.77 | Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report. ( Baszko-Błaszyk, D; Ochmańska, K; Sowiński, J; Waśko, R, 2011) |
| "Mitotane treatment in adrenocortical carcinoma (ACC) results in unreliable measurement of serum total cortisol (TC) levels because of an elevation in corticosteroid-binding globulin (CBG)." | 7.76 | Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. ( Ajodha, S; Akker, SA; Alexandraki, KI; Allolio, B; Christ-Crain, M; Drake, WM; Edwards, R; Fassnacht, M; Grossman, AB; Kaltsas, GA; le Roux, CW, 2010) |
| "To progress in the stratification of the first-line therapeutic management of metastatic adrenocortical carcinoma (ACC), we searched for prognostic parameters of survival in patients treated with combined mitotane- and cisplatinum-based chemotherapy as first-line." | 7.76 | Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. ( Al Ghuzlan, A; Baudin, E; Caillou, B; Castaing, M; Chanson, P; de Baere, T; Dromain, C; Elias, D; Leboulleux, S; Malandrino, P; Paci, A; Schlumberger, M; Travagli, JP; Young, J, 2010) |
| "A 57-year-old white woman with metastases to lungs and liver from virilizing adrenocortical carcinoma (ACC) was treated with radical nephroadrenalectomy followed by oral mitotane 3 to 6 g/day for 5 months." | 7.75 | Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy. ( Banerjee, TK; Chalasani, S; McKenzie, AK; Vats, HS, 2009) |
| "Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma." | 7.74 | Adjuvant mitotane treatment for adrenocortical carcinoma. ( Allolio, B; Ambrosi, B; Angeli, A; Arvat, E; Berruti, A; Bollito, E; Bruzzi, P; Buci, L; Conton, PA; Daffara, F; Dogliotti, L; Fassnacht, M; Grossrubatscher, E; Hahner, S; Koschker, AC; Loli, P; Lombardi, G; Mannelli, M; Mantero, F; Papotti, M; Reimondo, G; Rossetto, R; Saeger, W; Sperone, P; Tauchmanova, L; Terzolo, M, 2007) |
| "Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented." | 7.69 | Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. ( Fleuren, GJ; Goslings, BM; Haak, HR; Hermans, J; Krans, HM; Lentjes, EG; van de Velde, CJ, 1994) |
| "Cabazitaxel has a manageable toxicity profile but is poorly active as second/third-line treatment in advanced ACC patients." | 7.11 | Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ( Abate, A; Ambrosini, R; Berruti, A; Canu, L; Cosentini, D; Ferrari, VD; Gianoncelli, A; Grisanti, S; Laganà, M; Sigala, S; Terzolo, M; Tiberio, GAM; Turla, A; Zamparini, M, 2022) |
| " IMC-A12 was dosed at 10 mg/kg intravenously every 2 weeks." | 6.79 | The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. ( Agamah, E; Else, T; Hammer, GD; Hasseltine, EA; Hesseltine, EA; Lerario, AM; Ramm, CA; Rao, K; Shah, MH; Stadler, WM; Worden, FP, 2014) |
| "Mitotane plasma levels were determined using high-performance liquid chromatography." | 6.72 | Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. ( Callefe, LG; Ferman, S; Figueiredo, BC; Lichtvan, LL; Oliveira, BH; Parise, GA; Pianovski, MA; Piovezan, GC; Santana, MH; Stinghen, ST; Voss, SZ; Zancanella, P, 2006) |
| "Mitotane was stopped at gestation week 6." | 6.49 | Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature. ( Blumenfeld, Z; Bronshtein, M; Jaffe, A; Salmon, A; Tripto-Shkolnik, L, 2013) |
| "His aldosterone/renin ratio was high and plasma renin activity was low." | 5.91 | [A Case of Aldosterone-Producing Adrenocortical Carcinoma]. ( Asai, S; Hashimoto, K; Ishihara, M; Kanamaru, S; Katsushima, H; Nakayasu, R; Oshiro, H; Shimizu, Y; Son, C; Tsuji, K; Utsunomiya, N, 2023) |
| "Mitotane TR was significantly reduced in the SPL group, as was time-in-range to progression." | 5.72 | Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients. ( Haberbosch, L; Jumpertz von Schwartzenberg, R; Mai, K; Maurer, L; Sandforth, A; Spranger, J; Wernicke, C, 2022) |
| "The pathological diagnosis was adrenocortical carcinoma with negative surgical margin." | 5.72 | [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission]. ( Iinuma, K; Kato, D; Kawase, K; Kawase, M; Koie, T; Miyazaki, T; Nakai, C; Nakane, K; Namiki, S; Takai, M; Takeuchi, S; Takeuchi, Y; Tsuchiya, T; Ueda, S, 2022) |
| "At metastatic stage, treatment of adrenocortical carcinoma (ACC) relies in first line on mitotane therapy, combination of mitotane with locoregional therapies or cisplatin-based chemotherapy according to initial presentation." | 5.69 | Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE. ( Baudin, E; de la Fouchardiere, C; Debien, V; Do Cao, C; Drui, D; du Rusquec, P; Hadoux, J; Haissaguerre, M; Hescot, S; Le Tourneau, C; Libé, R; Massard, C; Vezzosi, D, 2023) |
| "Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high." | 5.69 | Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. ( Arlt, W; Bancos, I; Basile, V; Baudin, E; Berchialla, P; Berruti, A; Bertherat, J; Beuschlein, F; Bourdeau, I; Bovis, F; Bruzzi, P; Canu, L; Caron, P; Chabre, O; Chortis, V; Cosentini, D; Decoudier, B; Dusek, T; Ettaieb, MH; Fassnacht, M; Fragoso, MCBV; Giordano, R; Grisanti, S; Haak, HR; Hahner, S; Haissaguerre, M; Kastelan, D; Kimpel, O; Kroiss, M; Lacroix, A; Lasolle, H; Libé, R; Loli, P; Luconi, M; Megerle, F; Nölting, S; Perotti, P; Puglisi, S; Quinkler, M; Reimondo, G; Sormani, MP; Stigliano, A; Terzolo, M; Zatelli, MC, 2023) |
| "Mitotane was administered to 2 patients as an adjuvant therapy and to 8 patients for systemic control." | 5.62 | Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. ( Fukuda, N; Hayashi, N; Inamura, K; Komai, Y; Nakano, K; Numao, N; Ohmoto, A; Ono, M; Sato, Y; Shigematsu, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yonese, J; Yuasa, T; Yunokawa, M, 2021) |
| "Mitotane, the standard treatment for ACC, impairs adrenocortical steroid biosynthesis and cholesterol metabolism." | 5.56 | Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. ( Basile, V; Biasi, F; Caccia, C; Germano, A; Iaia, N; Leoni, V; Poli, G; Puglisi, S; Rossin, D; Saba, L; Terzolo, M, 2020) |
| "Under the diagnosis of stage IV adrenocortical carcinoma, mitotane therapy was started in May 2013." | 5.51 | [A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP]. ( Hanai, T; Nakayama, T; Onuki, T; Suzuki, K; Yamashita, D, 2019) |
| "Mitotane effect was explored stratifying patients by staging (stage I-II vs stage III), hormone secretion (yes vs no) and Ki67 index." | 5.51 | Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Saba, L; Terzolo, M; Veltri, A; Volante, M, 2019) |
| "Adrenal insufficiency is common with mitotane use and aggressive treatment with steroid supplementation should be considered when appropriate to avoid excess toxicities." | 5.46 | Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. ( Chou, J; Gerst, S; Gopalan, A; Hrabovsky, A; Kampel, L; Katz, S; Kelly, C; Lung, B; Raj, N; Reidy-Lagunes, DL; Saltz, LB; Untch, BR, 2017) |
| "Adrenocortical carcinoma is a rare tumour with high malignancy and poor prognosis." | 5.46 | Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane. ( Czuczwar, P; Paszkowski, T; Szkodziak, F; Szkodziak, PR; Woźniak, S, 2017) |
| "Central hypothyroidism was described previously in mitotane-treated patients but data on its prevalence and time of occurrence are limited." | 5.41 | Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. ( Bourdeau, I; Caron, P; Godemel, S; Grunenwald, S; Lacroix, A; Le, XK; Mourot, A; Olney, HJ; Poirier, J, 2023) |
| "We aimed at investigating in vitro the cytotoxic activity (determined using WST-1, apoptosis and cell cycle assays) of gemcitabine, alone or in combination with mitotane, in mitotane-sensitive H295R and mitotane-insensitive SW-13 cells." | 5.40 | Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. ( Berruti, A; Carturan, S; Germano, A; Lo Buono, N; Papotti, M; Rapa, I; Terzolo, M; Volante, M, 2014) |
| "The pregnancy was complicated by fetal exposure to mitotane and dexamethasone." | 5.37 | Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure. ( Burym, C; Cronin, CM; Kojori, F; Salamon, E; Sellers, EA, 2011) |
| "A 58-year-old man had adrenocortical carcinoma in the right adrenal gland." | 5.30 | Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999) |
| "The management of patients with advanced/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen." | 5.22 | Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen. ( Abate, A; Berruti, A; Consoli, F; Cosentini, D; Cremaschi, V; Ferrari, VD; Grisanti, S; Laganà, M; Sigala, S; Turla, A, 2022) |
| "Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy for patients with early-stage adrenocortical carcinoma (ACC)." | 5.22 | Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? ( Abate, A; Berruti, A; Cosentini, D; Cremaschi, V; Grisanti, S; Laganà, M; Rossini, E; Sigala, S; Tamburello, M; Turla, A, 2022) |
| "Mitotane is the drug of choice in patients with adrenocortical carcinoma." | 5.19 | Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring. ( den Hartigh, J; Derijks, LJ; Eekhoff, EM; Ettaieb, MH; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TM; Neef, C, 2014) |
| "Mitotane is the only approved drug for treatment of adrenocortical carcinoma." | 5.17 | Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. ( Allolio, B; Baudin, E; Chadarevian, R; Fassnacht, M; Haak, HR; Kerkhofs, TM; Leboulleux, S; Mantero, F; Mueller, HH; Skogseid, B; Terzolo, M, 2013) |
| "Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor." | 5.17 | Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. ( Allolio, B; Arlt, W; Bertagna, X; Bertherat, J; Beuschlein, F; Chortis, V; Fassnacht, M; Hahner, S; Hughes, BA; Karavitaki, N; Libé, R; Mannelli, M; Mantero, F; Nightingale, P; O'Neil, DM; Opocher, G; Porfiri, E; Quinkler, M; Schneider, P; Shackleton, CH; Sherlock, M; Stewart, PM; Taylor, AE; Terzolo, M; Tomlinson, JW, 2013) |
| "The benefit-to-risk ratio of a high-dose strategy at the initiation of mitotane treatment of adrenocortical carcinoma (ACC) remains unknown." | 5.16 | High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. ( Al Ghuzlan, A; Baudin, E; Borget, I; Chanson, P; Deandreis, D; Drouard, L; Leboulleux, S; Mauclère-Denost, S; Paci, A; Schlumberger, M; Tabarin, A; Young, J, 2012) |
| "We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks." | 5.16 | Combination chemotherapy in advanced adrenocortical carcinoma. ( Allolio, B; Arlt, W; Baudin, E; Berruti, A; Beuschlein, F; de la Fouchardière, C; Edgerly, M; Fassnacht, M; Fojo, T; Gelderblom, H; Haak, H; Hahner, S; Hermsen, I; Jarzab, B; Kenn, W; Kroiss, M; Lacroix, A; Leboulleux, S; Mantero, F; Müller, HH; Quinkler, M; Schade-Brittinger, C; Schlumberger, M; Schteingart, DE; Sender, M; Skogseid, B; Sorbye, H; Sperone, P; Stepan, V; Sundin, A; Tabarin, A; Terzolo, M; Torpy, DJ; Weismann, D; Welin, S; Willenberg, HS; Wilmink, H, 2012) |
| "We designed a single-center retrospective study to assess the QT interval duration and to describe cardio vascular events among patients treated with mitotane for a adrenocortical carcinoma (ACC)." | 5.16 | No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. ( Abbas, H; Bertagna, X; Chaderevian, R; Cohen, A; Dufaitre, G; Ederhy, S; Libé, R, 2012) |
| " Both patients were diagnosed with adrenocortical carcinoma (ACC) and were exposed to mitotane." | 5.15 | Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ( Gelderblom, H; Guchelaar, HJ; Hartigh, Jd; Ploeger, BA; Romijn, JA; van Erp, NP, 2011) |
| "A recent nonrandomized interinstitutional study reported that adjuvant mitotane following surgery for adrenocortical carcinoma (ACC) was associated with decreased recurrence." | 5.14 | Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. ( Callender, GG; Evans, DB; Grubbs, EG; Lee, JE; Perrier, ND; Phan, AT; Xing, Y, 2010) |
| "Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC)." | 5.12 | Pharmacological profile and effects of mitotane in adrenocortical carcinoma. ( Acco, A; Bach, C; Bonatto, SJR; Corso, CR; de Figueiredo, BC; de Souza, LM, 2021) |
| "Mitotane is the only drug registered specifically for adrenocortical carcinoma." | 5.12 | How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives. ( Ettaieb, MHT; Haak, HR; Kerkhofs, TMA; Steenaard, RV, 2021) |
| "Mitotane as tablet form is currently the standard treatment for adrenocortical carcinoma." | 5.12 | The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging. ( Ahmad, T; Groll, J; Haider, MS; Kroiss, M; Luxenhofer, R; Scherf-Clavel, O, 2021) |
| "A previous Southwest Oncology Group study demonstrated a 30% response rate with the combination of cisplatin and mitotane in the treatment of patients with metastatic adrenocortical carcinoma." | 5.09 | Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. ( Baker, LH; Balcerzak, SP; Crawford, ED; Lew, D; Miller, GJ; Williamson, SK, 2000) |
| "The use of either mitotane or chemotherapy in the treatment of advanced adrenocortical carcinoma (ACC) has led to scanty and controversial results." | 5.08 | Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. ( Angeli, A; Berruti, A; Dogliotti, L; Pia, A; Terzolo, M, 1998) |
| "Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC)." | 5.05 | Next-generation therapies for adrenocortical carcinoma. ( Altieri, B; Fassnacht, M; Kroiss, M; Ronchi, CL, 2020) |
| "The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy." | 4.98 | Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( Liang, J; Liu, Z; Lu, Y; Tang, Y; Zhu, Y; Zou, Z, 2018) |
| "Description of novel findings about the mechanism of action of mitotane and its activity as an adjunctive postoperative measure, or for treatment of advanced adrenocortical carcinoma." | 4.90 | Practical treatment using mitotane for adrenocortical carcinoma. ( Allasino, B; De Francia, S; Terzolo, M; Zaggia, B, 2014) |
| "Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, (o,p'-DDD)] is the only drug approved for the treatment for adrenocortical carcinoma (ACC) and has also been used for various forms of glucocorticoid excess." | 4.87 | Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Kroiss, M; Lutz, WK; Quinkler, M, 2011) |
| "Mitotane has been used for 50 years as the first-line drug in the treatment of disseminated adrenocortical carcinoma." | 4.86 | [Mitotane in the treatment of adrenal carcinoma]. ( Sane, T, 2010) |
| "A retrospective analysis showing that adjuvant mitotane may prolong recurrence-free survival in a large cohort of patients with radically resected adrenocortical carcinoma has recently been published." | 4.84 | Adjunctive treatment of adrenocortical carcinoma. ( Berruti, A; Terzolo, M, 2008) |
| "Treatment for advanced adrenocortical carcinoma (ACC) consists of mitotane alone or combined with etoposide, doxorubicin, and cisplatin (EDP)." | 4.31 | Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma. ( Abbas, H; Altieri, B; Asia, M; Detomas, M; Elhassan, YS; Mangone, A; Mantovani, G; Prete, A; Ronchi, CL, 2023) |
| "Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied." | 4.31 | Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study. ( Alberti, A; Berruti, A; Cappelli, C; Cosentini, D; Cremaschi, V; Delbarba, A; Facondo, P; Ferlin, A; Grisanti, S; Laganà, M; Pezzaioli, LC, 2023) |
| " Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy for which mitotane (MTT) treatment represents the first-line therapy, though its efficacy is limited to a therapeutic window level (14-20 mg/L)." | 4.31 | Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane. ( Amedei, A; Baldi, S; Cantini, G; Canu, L; Di Gloria, L; Fei, L; Luconi, M; Nannini, G; Nesi, G; Niccolai, E; Propato, AP; Puglisi, S; Ramazzotti, M, 2023) |
| "Mitotane is a chiral drug used to treat adrenocortical carcinoma, being metabolized to the o,p'-dichlorodiphenyl acetic acid (o,p'-DDA), also a chiral compound." | 4.31 | Two-dimensional chromatography for enantiomeric analysis of mitotane and its metabolite o,p'-DDA in patients with adrenocortical carcinoma indicates enantioselective metabolism. ( Bach de Assis, C; Cavalcante de Figueiredo, B; Cruz Bonk, B; de Almeida Veiga, A; de Toledo Nogueira, B; Lada Degaut Pontes, F; Mera de Souza, L; Regina Rocha Martins, L; Rita Corso, C; Stadler, G, 2023) |
| " A 33-year-old woman who underwent surgery for adrenocortical carcinoma and treated with mitotane was referred for infertility." | 4.12 | Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma. ( Belin, F; Bry-Gauillard, H; Grynberg, M; Massin, N; Renoult-Pierre, P; Sifer, C; Vinolas, C; Young, J, 2022) |
| "Mitotane is the only approved drug for treating adrenocortical carcinoma (ACC)." | 4.12 | Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. ( Abate, A; Berruti, A; Cosentini, D; Fiorentini, C; Grisanti, S; Grosso, E; Hantel, C; Laganà, M; Memo, M; Rossini, E; Scatolini, M; Sigala, S; Tamburello, M; Tiberio, GAM, 2022) |
| "Patients with adrenocortical carcinoma (ACC) are frequently on mitotane therapy for a long time period." | 4.12 | Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. ( Al Ghuzlan, A; Baudin, E; Berruti, A; Cosentini, D; Deschamps, F; Frigerio, M; Gasparotti, R; Grisanti, S; Hadoux, J; Laganà, M; Lamartina, L; Libè, R; Maroldi, R; Pedersini, R; Terzolo, M; Valsecchi, C; Zamparini, M, 2022) |
| "Adjuvant treatment with mitotane and chemotherapy is recommended for paediatric advanced and metastatic adrenocortical carcinoma (ACC)." | 4.12 | Key factors for effective mitotane therapy in children with adrenocortical carcinoma. ( Brecht, I; Frühwald, MC; Kuhlen, M; Kunstreich, M; Lessel, L; Mier, P; Redlich, A; Schewe, DM; Schneider, D; Vorwerk, P, 2022) |
| "Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)." | 4.02 | Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. ( Corssmit, EPM; Cusato, J; D'Avolio, A; Eekhoff, M; Ettaieb, MHT; Feelders, RA; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TMA; Kerstens, MN; Moes, DJAR; Swen, JJ; Timmers, HJLM; van der Straaten, RJHM; van Deun, L; Yin, A, 2021) |
| "Mitotane is used in the treatment of adrenocortical carcinoma (ACC)." | 4.02 | Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients. ( Andreassen, M; Daugaard, G; Krogh, J; Vikner, ME, 2021) |
| "Following initial surgery, patients with adrenocortical carcinoma (ACC) are commonly treated with the adrenolytic substance mitotane in an adjuvant or therapeutic setting." | 4.02 | Predicitve Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. ( Beuschlein, F; Bluemel, C; Fassnacht, M; Hahner, S; Loewe, R; Pfluger, T; Reincke, M; Rogowski-Lehmann, N, 2021) |
| "European and French guidelines for ENSAT stage IV low tumor burden or indolent adrenocortical carcinoma (ACC) recommend a combination of mitotane and locoregional treatments (LRT) as first-line treatment." | 4.02 | Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma. ( Al Ghuzlan, A; Baudin, E; Boilève, A; de Baere, T; Deschamps, F; Faron, M; Hadoux, J; Hescot, S; Lamartina, L; Leboulleux, S; Mathy, E; Roux, C; Tselikas, L, 2021) |
| "Patients with adrenocortical carcinoma (ACC) often fail mitotane treatment and deal with severe toxicity, marking the relevance of predictive parameters for treatment outcome." | 3.96 | The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. ( Creemers, SG; de Herder, WW; Dogan, F; Feelders, RA; Franssen, GJH; Hofland, LJ; van Koetsveld, PM, 2020) |
| "Mitotane is an adrenolytic drug that is used as an adjuvant to treat adrenocortical carcinoma." | 3.96 | Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations. ( Abrahamsson, G; Ahlman, H; Ekerhovd, E; Janson, PO; Jansson, S; Norström, A; Wängberg, B, 2020) |
| "Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20%, and adverse drug effects are frequent." | 3.96 | Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. ( Altieri, B; Basile, V; Berruti, A; Canu, L; Della Casa, S; Fassnacht, M; Fragoso, MCBV; Kircher, S; Kroiss, M; Lacombe, AMF; Landwehr, LS; Megerle, F; Paiva, I; Ronchi, CL; Sbiera, S; Schreiner, J; Terzolo, M; Volante, M; Weigand, I; Zerbini, MCN, 2020) |
| "Mitotane causes hypercholesterolemia in patients with adrenocortical carcinoma (ACC)." | 3.96 | Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth. ( Avena, P; Barile, SN; Casaburi, I; Chimento, A; De Luca, A; Fallo, F; Lasorsa, FM; Lerario, AM; Malivindi, R; Nocito, MC; Palmieri, L; Pezzani, R; Pezzi, V; Pilon, C; Rago, V; Sculco, S; Sirianni, R; Trotta, F, 2020) |
| "Low-dose mitotane has been widely used for many decades in patients with advanced adrenocortical carcinoma (ACC), which exhibited good safety profiles compared with the high-dose regimen." | 3.96 | A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring. ( Deng, JH; Fu, Q; Liu, X; Mei, D; Tang, Y; Zhang, B, 2020) |
| " Mitotane therapy of adrenocortical carcinoma (ACC) has been shown to act through lipid-induced ER-stress." | 3.91 | Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. ( Fassnacht, M; Kendl, S; Kroiss, M; Sbiera, I; Sbiera, S; Weigand, I, 2019) |
| "Mitotane (also termed o,p'‑DDD) is the most effective therapy for advanced adrenocortical carcinoma (ACC)." | 3.91 | Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. ( Amazit, L; Baudin, E; Boulate, G; Hescot, S; Lombes, A; Lombes, M; Naman, A; Paci, A; Pussard, E; Seck, A, 2019) |
| "Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce." | 3.88 | Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. ( Beuschlein, F; Fassnacht, M; Hahner, S; Herrmann, W; Kroiss, M; Megerle, F; Pulzer, A; Quinkler, M; Ronchi, CL; Schloetelburg, W, 2018) |
| " Recent studies have shown that an important component in the mechanism of action of mitotane, the only approved drug for the medical treatment of adrenocortical carcinoma (ACC), is represented by activation of ER stress through inhibition of the SOAT1 enzyme and accumulation of toxic lipids." | 3.88 | The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. ( Benhida, R; Doghman-Bouguerra, M; Lalli, E; Rocchi, S; Ronco, C; Ruggiero, C, 2018) |
| "Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity." | 3.88 | CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. ( Berruti, A; De Francia, S; Germano, A; Perotti, P; Rapa, I; Saba, L; Terzolo, M; Volante, M, 2018) |
| "Mitotane is used for the treatment of adrenocortical carcinoma." | 3.88 | Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients. ( Arshad, U; Fassnacht, M; Frechen, S; Fuhr, U; Hamacher, S; Herterich, S; Kroiss, M; Kurlbaum, M; Megerle, F; Taubert, M, 2018) |
| "Mitotane is a cytostatic antineoplastic agent that is used in the treatment of adrenocortical carcinoma and Cushing's syndrome." | 3.88 | Mitotane-induced dyspnoea: an unusual side effect. ( Adhikari, S; Amjad, W; Farooq, AU; Kochar, T, 2018) |
| "In 2007, a retrospective case-control study provided evidence that adjuvant mitotane prolongs recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC)." | 3.85 | Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. ( Arvat, E; Berruti, A; Boscaro, M; Claps, M; Daffara, F; Fassnacht, M; Grisanti, S; Hahner, S; Loli, P; Mannelli, M; Porpiglia, F; Pulzer, A; Terzolo, M; Tiberio, G; Volante, M; Zaggia, B, 2017) |
| " The present in-vitro study shows that AMG 900 inhibits aurora kinases in adrenocortical carcinoma cells." | 3.85 | The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line. ( Andrade, AF; Antonini, SRR; Borges, KS; Marco Antonio, DS; Scrideli, CA; Silveira, VS; Tone, LG; Vasconcelos, EJR, 2017) |
| "Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p'-DDE (dichlorodiphenylethene) and o,p'-DDA (dichlorodiphenylacetate)." | 3.85 | Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. ( Allegra, S; Berruti, A; Carrella, S; Cusato, J; D'Avolio, A; Daffara, FC; De Francia, S; De Martino, F; Di Carlo, F; Ferrero, A; Piccione, FM; Pirro, E; Tampellini, M; Terzolo, M, 2017) |
| "Oral mitotane (o,p'-DDD) is a cornerstone of medical treatment for adrenocortical carcinoma (ACC)." | 3.83 | Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. ( Fassnacht, M; Heinz, W; Kendl, S; Klinker, H; Kroiss, M; Lapa, C; Plonné, D; Ronchi, CL; Sbiera, S; Schirbel, A; Schirmer, D; Zink, M, 2016) |
| "Current treatment guidelines recommend adjuvant mitotane after resection of adrenocortical carcinoma with high-risk features (eg, tumor rupture, positive margins, positive lymph nodes, high grade, elevated mitotic index, and advanced stage)." | 3.83 | Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. ( Duh, QY; Ethun, CG; Fields, RC; Gad, S; Glenn, J; Hatzaras, I; Jin, LX; Keplinger, K; Kiernan, CM; Levine, EA; Maithel, SK; Mansour, JC; Pawlik, TM; Phay, JE; Postlewait, LM; Poultsides, GA; Prescott, JD; Salem, A; Seiser, N; Shenoy, R; Sicklick, JK; Solorzano, CC; Staley, CA; Tran, TB; Votanopoulos, KI; Wang, TS; Weber, SM; Yopp, AC, 2016) |
| "Mitotane has been used for more than 5 decades as therapy for adrenocortical carcinoma (ACC)." | 3.83 | Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature. ( Bourdeau, I; Cohade, C; El Ghorayeb, N; Lacroix, A; Latour, M; Mazzuco, TL; Olney, H; Perrotte, P; Rondeau, G; Sabourin, A, 2016) |
| "Evaluation of patient characteristics and mitotane use in the treatment of adrenocortical carcinoma (ACC) over a 4-year period in Belgium." | 3.83 | Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients. ( Banh, C; Bex, M; Chadarevian, R; Gil, T; Maiter, D; T'Sjoen, G; Vroonen, L, 2016) |
| "Treatment of patients with adrenocortical carcinomas (ACC) with mitotane and/or chemotherapy is often associated with toxicity and poor tumor response." | 3.83 | Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene. ( Creemers, SG; de Herder, WW; Feelders, RA; Franssen, GJ; Hofland, LJ; Korpershoek, E; van den Dungen, ES; van Kemenade, FJ; van Koetsveld, PM, 2016) |
| "Mitotane is the only drug approved for treatment of the orphan disease adrenocortical carcinoma (ACC) and was recently shown to be the first clinically used drug acting through endoplasmic reticulum (ER)-stress induced by toxic lipids." | 3.83 | Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. ( Fassnacht, M; Kendl, S; Kroiss, M; Kurlbaum, M; Sbiera, S, 2016) |
| "Mitotane is the drug of choice in medical treatment of adrenocortical carcinoma." | 3.81 | Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma. ( den Hartigh, J; Derijks, LJ; Ettaieb, H; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TM; Neef, K, 2015) |
| "Mitotane is an adrenolytic and anticortisolic drug used in adrenocortical carcinoma (ACC), Cushing's disease (CD), and ectopic ACTH syndrome." | 3.81 | Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. ( Bachelot, A; Baudin, E; Bernard, V; Bry-Gauillard, H; Chanson, P; Crinière, L; Do Cao, C; Droumaguet, C; Guignat, L; Leboulleux, S; Maiter, D; Pierre, P; Salenave, S; Santulli, P; Schlumberger, M; Touraine, P; Young, J, 2015) |
| "Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high-lipid-containing tissues." | 3.81 | Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. ( Baudin, E; Broutin, S; Cockenpot, F; Guerin, M; Hescot, S; Huby, T; Lombès, M; Paci, A; Seck, A; Young, J, 2015) |
| "Mitotane (o,p'DDD) is the most effective treatment of advanced adrenocortical carcinoma (ACC) but its mechanism of action remains unknown." | 3.80 | The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. ( Al Ghuzlan, A; Baudin, E; Brailly-Tabard, S; Hescot, S; Lombès, M; Paci, A; Seck, A; Slama, A; Trabado, S; Viengchareun, S; Young, J, 2014) |
| "Mitotane is currently employed as adjuvant therapy as well as in the medical treatment of adrenocortical carcinoma (ACC), alone or in combination with chemotherapeutic agents." | 3.80 | Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. ( Benfini, K; Di Pasquale, C; Falletta, S; Feo, C; Gagliano, T; Gentilin, E; Tagliati, F; Tassinari, M; Uberti, ED; Zatelli, MC, 2014) |
| "We herein report a case of marked transient hypercholesterolemia in a man receiving low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma." | 3.80 | Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma. ( Inazu, A; Kawashiri, MA; Mabuchi, H; Nohara, A; Tada, H; Yamagishi, M, 2014) |
| "Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC)." | 3.79 | Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. ( Al Ghuzlan, A; Allolio, B; Ardito, A; Baudin, AE; Berruti, A; Daffara, F; De Francia, S; deVries, JH; Fassnacht, M; Feelders, RA; Haak, HR; Kroiss, M; Leboulleux, S; Perotti, P; Terzolo, M; Volante, M; Zaggia, B, 2013) |
| "Mitotane is a widely used drug in the therapy of adrenocortical carcinoma (ACC)." | 3.79 | Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. ( Doghman, M; Lalli, E, 2013) |
| "In patients with adrenocortical carcinoma (ACC) mitotane activity has been suggested to depend on plasma levels 14 mg/liter or greater and metabolite formation." | 3.77 | Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. ( Allolio, B; Baudin, E; Berruti, A; Chadarevian, R; Daffara, F; den Hartigh, J; Fassnacht, M; Haak, HR; Hermsen, IG; Houterman, S; Leboulleux, S; Schlumberger, M; Terzolo, M, 2011) |
| "We present the case of a female patient with virilising adrenocortical carcinoma treated surgically who conceived during adjuvant treatment with mitotane." | 3.77 | Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report. ( Baszko-Błaszyk, D; Ochmańska, K; Sowiński, J; Waśko, R, 2011) |
| "Mitotane treatment in adrenocortical carcinoma (ACC) results in unreliable measurement of serum total cortisol (TC) levels because of an elevation in corticosteroid-binding globulin (CBG)." | 3.76 | Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. ( Ajodha, S; Akker, SA; Alexandraki, KI; Allolio, B; Christ-Crain, M; Drake, WM; Edwards, R; Fassnacht, M; Grossman, AB; Kaltsas, GA; le Roux, CW, 2010) |
| "Mitotane (o,p'-DDD) is considered to be the drug of choice in the treatment of nonresectable and metastasized adrenocortical carcinoma." | 3.76 | Development of microemulsion of mitotane for improvement of oral bioavailability. ( Ajana, I; Astier, A; Attivi, D; Demoré, B; Gibaud, S, 2010) |
| "To progress in the stratification of the first-line therapeutic management of metastatic adrenocortical carcinoma (ACC), we searched for prognostic parameters of survival in patients treated with combined mitotane- and cisplatinum-based chemotherapy as first-line." | 3.76 | Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. ( Al Ghuzlan, A; Baudin, E; Caillou, B; Castaing, M; Chanson, P; de Baere, T; Dromain, C; Elias, D; Leboulleux, S; Malandrino, P; Paci, A; Schlumberger, M; Travagli, JP; Young, J, 2010) |
| "Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma." | 3.74 | Adjuvant mitotane treatment for adrenocortical carcinoma. ( Allolio, B; Ambrosi, B; Angeli, A; Arvat, E; Berruti, A; Bollito, E; Bruzzi, P; Buci, L; Conton, PA; Daffara, F; Dogliotti, L; Fassnacht, M; Grossrubatscher, E; Hahner, S; Koschker, AC; Loli, P; Lombardi, G; Mannelli, M; Mantero, F; Papotti, M; Reimondo, G; Rossetto, R; Saeger, W; Sperone, P; Tauchmanova, L; Terzolo, M, 2007) |
| "Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chloro-phenyl) ethane (o,p'-DDD), is a compound that represents the effective agent in the treatment of the adrenocortical carcinoma (ACC), able to block cortisol synthesis." | 3.74 | Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. ( Borro, M; Brunetti, E; Bucci, B; Cerquetti, L; Gentile, G; Misiti, S; Piergrossi, P; Simmaco, M; Stigliano, A; Toscano, V, 2008) |
| "Surgery with immediate adjuvant long term mitotane administration was the most effective form of therapy for patients with adrenocortical carcinoma." | 3.69 | Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. ( Kasperlik-Załuska, AA; Makowska, AM; Migdalska, BM; Zgliczyński, S, 1995) |
| "Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented." | 3.69 | Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. ( Fleuren, GJ; Goslings, BM; Haak, HR; Hermans, J; Krans, HM; Lentjes, EG; van de Velde, CJ, 1994) |
| "Cabazitaxel has a manageable toxicity profile but is poorly active as second/third-line treatment in advanced ACC patients." | 3.11 | Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ( Abate, A; Ambrosini, R; Berruti, A; Canu, L; Cosentini, D; Ferrari, VD; Gianoncelli, A; Grisanti, S; Laganà, M; Sigala, S; Terzolo, M; Tiberio, GAM; Turla, A; Zamparini, M, 2022) |
| "Although adrenocortical carcinoma (ACC) during pregnancy is rare, a retrospective review of a case series at our hospital revealed that almost one third of our patients were women in childbearing age." | 3.01 | Pregnancy in patients with adrenocortical carcinoma: a case-based discussion. ( Basile, V; Puglisi, S; Sperone, P; Terzolo, M, 2023) |
| " IMC-A12 was dosed at 10 mg/kg intravenously every 2 weeks." | 2.79 | The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. ( Agamah, E; Else, T; Hammer, GD; Hasseltine, EA; Hesseltine, EA; Lerario, AM; Ramm, CA; Rao, K; Shah, MH; Stadler, WM; Worden, FP, 2014) |
| "Treatment of refractory adrenocortical carcinoma (ACC) is not established." | 2.77 | Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. ( Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Kroiss, M; Lankheet, N; Laubner, K; Müller, HH; Pöllinger, A; Quinkler, M; Strasburger, CJ; van Erp, NP, 2012) |
| "Mitotane plasma levels were determined using high-performance liquid chromatography." | 2.72 | Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. ( Callefe, LG; Ferman, S; Figueiredo, BC; Lichtvan, LL; Oliveira, BH; Parise, GA; Pianovski, MA; Piovezan, GC; Santana, MH; Stinghen, ST; Voss, SZ; Zancanella, P, 2006) |
| " The therapeutic range is close and therefore dosage is difficult, mainly based on clinical signs." | 2.70 | [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels]. ( Heilmann, P; Nawroth, PP; Wagner, P; Ziegler, R, 2001) |
| "Adrenocortical carcinoma is a rare malignancy, often with poor outcomes." | 2.66 | American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach. ( Bancos, I; Else, T; Habra, M; Hamrahian, A; Kiseljak-Vassiliades, K; Levine, AC; Vaidya, A, 2020) |
| "Pheochromocytomas are present in approximately 4-7% of patients with adrenal incidentalomas." | 2.58 | Primary malignant tumors of the adrenal glands. ( Almeida, MQ; Bezerra-Neto, JE; Fragoso, MCBV; Latronico, AC; Mendonça, BB, 2018) |
| "Adrenocortical carcinoma is a rare disease with poor prognosis." | 2.55 | Understanding mitotane mode of action. ( Dworakowska, D; Szyszka, P; Waszut, U, 2017) |
| "Recent developments in the treatment of adrenocortical carcinoma (ACC) include diagnostic and prognostic risk stratification algorithms, increasing evidence of the impact of historical therapies on overall survival, and emerging targets from integrated epigenomic and genomic analyses." | 2.52 | Adrenocortical carcinoma. ( Baudin, E, 2015) |
| "Pheochromocytomas are derived from the adrenal medulla and present with symptoms caused by high secretion of catecholamines." | 2.50 | Rare adrenal tumors in children. ( Mihai, R, 2014) |
| "Adrenocortical carcinoma is a rare malignancy." | 2.50 | Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma. ( Nakamura, Y; Sasano, H; Satoh, F, 2014) |
| "Even after complete surgery, recurrence is frequent and adjuvant mitotane treatment improves outcome, but uncertainty exists as to whether all patients benefit from this therapy." | 2.49 | Update in adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Kroiss, M, 2013) |
| "Mitotane was stopped at gestation week 6." | 2.49 | Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature. ( Blumenfeld, Z; Bronshtein, M; Jaffe, A; Salmon, A; Tripto-Shkolnik, L, 2013) |
| "Adrenocortical carcinomas are rare in children and sometimes occur in patients with predisposing syndrome like Li-Fraumeni or Beckwith-Wiedemann syndromes." | 2.47 | [Management of adrenocortical carcinomas in children]. ( Aubert, S; Delebarre, M; Leblond, P, 2011) |
| "Adrenocortical carcinoma with tumor thrombus and concomitant testosterone production is a rare entity." | 2.47 | Surgical resection of a virilizing adrenal mass with extensive tumor thrombus. ( Ciancio, G; Gahan, J; Gorin, MA; Salerno, TA; Shirodkar, SP, 2011) |
| " Several important questions remain to be addressed such as the optimal dose and most effective dosing interval, when to use the metronomic approach in the natural history of the disease, the choice of cytotoxic drugs, and the most efficacious way to integrate metronomic chemotherapy with standard therapy protocols." | 2.47 | Metronomic therapy concepts in the management of adrenocortical carcinoma. ( Ardito, A; Bellini, E; Berruti, A; Daffara, F; Perotti, P; Saini, A; Sperone, P; Terzolo, M, 2011) |
| "Androgen-secreting adrenal cancers are extremely rare malignancies, accounting for only a tiny proportion of the total number of women presenting with signs of androgen excess." | 2.46 | Androgen- and estrogen-secreting adrenal cancers. ( Bharwani, N; Cavlan, D; Grossman, A, 2010) |
| "Sometimes the adrenocortical carcinoma is associated with tumour syndromes such as the Beckwith-Wiedemann and Li-Fraumeni syndrome; however, most tumours are sporadic." | 2.44 | Adrenocortical carcinoma. ( Haak, HR; van de Weijer, R; van Ditzhuijsen, CI, 2007) |
| "Mitotane has remained the preferred adjuvant treatment agent, showing modest effect in patients with unresectable, residual or metastatic disease." | 2.43 | Adrenocortical carcinoma. ( Roman, S, 2006) |
| "Therapy in patients with adrenocortical carcinoma is less satisfactory." | 2.42 | [Diagnosis and treatment for adrenocortical carcinoma]. ( Iihara, M; Obara, T, 2004) |
| "Adrenocortical carcinoma is a rare tumor with an annual incidence of 1 to 2 cases per million people." | 2.42 | [Adrenocortical carcinoma and its treatment]. ( Bednarek-Tupikowska, G; Florczak, A; Tupikowski, W, 2004) |
| "Adrenocortical cancers are relatively rare endocrine tumors that usually present when hormonally active or after they have become large and metastasis has occurred." | 2.40 | Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies. ( Demeure, MJ; Somberg, LB, 1998) |
| "To report a rare case of a metastatic adrenocortical carcinoma (ACC) that achieve a complete and a long-term remission." | 1.91 | Long-term complete remission of metastatic adrenocortical carcinoma. ( Álvarez-Escolá, C; Cárdenas-Salas, J; Castelo, B; González-Sanchez, JA; Regojo, RM, 2023) |
| "The management of adrenocortical carcinoma (ACC) recurrences remains controversial, and we present herein our experience with postoperative ACC recurrences." | 1.91 | The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients. ( Basile, V; Berchialla, P; Borin, C; Calabrese, A; Fiori, C; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Terzolo, M; Veltri, A; Volante, M, 2023) |
| "Mitotane therapy was initiated in 29 patients in the postoperative period, 33 patients were under dynamic observation without concomitant drug treatment." | 1.91 | [Morphological predictors of the efficacy of mitotane therapy in adrenocortical cancer]. ( Beltsevich, DG; Porubayeva, EE; Tkachuk, AV; Urusova, LS, 2023) |
| "The prognosis of adrenocortical carcinoma (ACC) is poor but highly variable." | 1.91 | Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience. ( Huang, CJ; Lin, LY; Ng, XN; Pan, LH; Yen, CC, 2023) |
| "Because of the rarity of adrenocortical cancer (ACC), only a few population-based studies are available, and they reported limited details in the characterization of patients and their treatment." | 1.91 | New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study. ( Altieri, B; Arvat, E; Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Cannavò, S; Canu, L; Ceccato, F; Di Dalmazi, G; Ferraù, F; Fiori, C; Grisanti, S; Laganà, M; Loli, P; Morelli, V; Perotti, P; Pia, A; Pivonello, R; Porpiglia, F; Puglisi, S; Reimondo, G; Scaroni, C; Stigliano, A; Terzolo, M; Urru, S; Violi, MA, 2023) |
| "Adrenocortical carcinomas are rare tumors, usually hyperfunctioning, with poor overall survival." | 1.91 | [Adrenocortical carcinoma in women of reproductive age]. ( Bergoglio, MT; Damilano, RA, 2023) |
| "His aldosterone/renin ratio was high and plasma renin activity was low." | 1.91 | [A Case of Aldosterone-Producing Adrenocortical Carcinoma]. ( Asai, S; Hashimoto, K; Ishihara, M; Kanamaru, S; Katsushima, H; Nakayasu, R; Oshiro, H; Shimizu, Y; Son, C; Tsuji, K; Utsunomiya, N, 2023) |
| "Mitotane TR was significantly reduced in the SPL group, as was time-in-range to progression." | 1.72 | Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients. ( Haberbosch, L; Jumpertz von Schwartzenberg, R; Mai, K; Maurer, L; Sandforth, A; Spranger, J; Wernicke, C, 2022) |
| "Reporting temporal trends in adrenocortical carcinoma (ACC) helps guide management strategies." | 1.72 | Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. ( Altameemi, L; Bazerbashi, H; Bedrose, S; Campbell, MT; Daher, M; Graham, PH; Gruschkus, SK; Habra, MA; Jimenez, C; Karam, JA; Lee, JE; Naing, A; Perrier, ND; Shah, AY; Sheth, RA; Subaiah, V; Varghese, J; Waguespack, SG; Wood, CG; Zhang, M, 2022) |
| "Mitotane (o, p'-DDD) is a molecule that was developed many years ago for adrenal cortical carcinoma, but no suitable pediatric dosage form is available for administration to young children." | 1.72 | Successful administration of mitotane (O, p'-DDD) in pediatric oncology. ( Defachelles, AS; Feutry, F; Fraipont, F; Marliot, G; Mercier, S; Naveau, M; Raimbault, S; Sakji, I; Stala, T; Strobbe, G; Villain, A, 2022) |
| "Mitotane chemotherapy is a standard but unproven adjuvant treatment that is associated with many complications, and its induction of hepatic CYP 3A4 enzymes necessitates adjustment of other medications." | 1.72 | Massive adrenocortical carcinoma presenting as peripheral edema: a case report. ( Goodkin, DA, 2022) |
| "The pathological diagnosis was adrenocortical carcinoma with negative surgical margin." | 1.72 | [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission]. ( Iinuma, K; Kato, D; Kawase, K; Kawase, M; Koie, T; Miyazaki, T; Nakai, C; Nakane, K; Namiki, S; Takai, M; Takeuchi, S; Takeuchi, Y; Tsuchiya, T; Ueda, S, 2022) |
| "Pediatric and adult adrenocortical carcinomas differ in many respects but treatment is often similar in both age groups." | 1.62 | Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines? ( Berruti, A; Cosentini, D; Grisanti, S; Laganà, M; Turla, A, 2021) |
| "Widespread metastatic adrenocortical carcinoma was confirmed on biopsy." | 1.62 | A rare case of right shoulder pain. ( Bansari, A; Kattan, JN; Radhakrishnan, NS, 2021) |
| "Mitotane was administered to 2 patients as an adjuvant therapy and to 8 patients for systemic control." | 1.62 | Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. ( Fukuda, N; Hayashi, N; Inamura, K; Komai, Y; Nakano, K; Numao, N; Ohmoto, A; Ono, M; Sato, Y; Shigematsu, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yonese, J; Yuasa, T; Yunokawa, M, 2021) |
| "Mitotane (MT) has been used for treatment of ACC for decades, either alone or in combination with cytotoxic chemotherapy." | 1.56 | A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models. ( Haider, MS; Kendl, S; Kroiss, M; Luxenhofer, R; Schreiner, J, 2020) |
| "Adjuvant therapy in adrenocortical carcinoma was initiated less frequently than suggested by current guidelines." | 1.56 | Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience. ( Bechter, OE; Bronswijk, MJH; Laenen, A, 2020) |
| "Mitotane is a key drug for the treatment of adrenal cortical carcinoma." | 1.56 | A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry. ( Ando, M; Fukushima, S; Hashida, T; Hirabatake, M; Sugioka, N; Yasui, H, 2020) |
| "Mitotane, the standard treatment for ACC, impairs adrenocortical steroid biosynthesis and cholesterol metabolism." | 1.56 | Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. ( Basile, V; Biasi, F; Caccia, C; Germano, A; Iaia, N; Leoni, V; Poli, G; Puglisi, S; Rossin, D; Saba, L; Terzolo, M, 2020) |
| "Despite the rarity of extra-adrenal adrenocortical carcinoma, presentation with an acute abdomen may occur, and the tumor may be found anywhere in the adrenal embryonic pathway." | 1.56 | Extra-adrenal, non-functional adrenocortical carcinoma presenting with acute abdomen: a case report. ( Ghorbani-Abdehgah, A; Mirsharifi, A; Naybandi Atashi, S; Sadeghian, E; Vasei, M, 2020) |
| "Under the diagnosis of stage IV adrenocortical carcinoma, mitotane therapy was started in May 2013." | 1.51 | [A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP]. ( Hanai, T; Nakayama, T; Onuki, T; Suzuki, K; Yamashita, D, 2019) |
| "The management of patients with adrenocortical carcinoma (ACC) is challenging." | 1.51 | In vitro antitumor activity of progesterone in human adrenocortical carcinoma. ( Berruti, A; Bonini, SA; Bosisio, D; Claps, M; Cosentini, D; Dalmiglio, C; Facchetti, F; Fiorentini, C; Fisogni, S; Fragni, M; Grisanti, S; Memo, M; Missale, C; Rossini, E; Salvi, V; Sigala, S; Terzolo, M; Tiberio, GAM; Vezzoli, S, 2019) |
| "Mitotane 6 g/day was started as standard therapy but it was responsible for severe central nervous system (CNS) and gastrointestinal toxicities associated with a 10 kg body weight loss." | 1.51 | A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment. ( Bacca, A; Bernini, G; Ciofi, L; Di Paolo, A, 2019) |
| "Mitotane effect was explored stratifying patients by staging (stage I-II vs stage III), hormone secretion (yes vs no) and Ki67 index." | 1.51 | Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Saba, L; Terzolo, M; Veltri, A; Volante, M, 2019) |
| "Adrenocortical carcinoma is a rare and aggressive malignancy with an incidence of 0." | 1.51 | A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore. ( Ali, A; Anwar, AW; Bakar, MA; Khan, MA; Khan, MS; Tariq, I, 2019) |
| "Mitotane treatment may be independently associated with better outcomes regardless of the tumor stage." | 1.48 | Prognostic factors in adrenocortical carcinoma: data from a large Polish series. ( Ambroziak, U; Cichocki, A; Koperski, Ł; Nowak, KM; Otto, M; Papierska, L; Roszkowska-Purska, K; Samsel, R; Zgliczyński, W; Łebek-Szatańska, A, 2018) |
| "Adrenal insufficiency is common with mitotane use and aggressive treatment with steroid supplementation should be considered when appropriate to avoid excess toxicities." | 1.46 | Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. ( Chou, J; Gerst, S; Gopalan, A; Hrabovsky, A; Kampel, L; Katz, S; Kelly, C; Lung, B; Raj, N; Reidy-Lagunes, DL; Saltz, LB; Untch, BR, 2017) |
| "Adrenocortical carcinoma is a rare tumour with high malignancy and poor prognosis." | 1.46 | Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane. ( Czuczwar, P; Paszkowski, T; Szkodziak, F; Szkodziak, PR; Woźniak, S, 2017) |
| "Systemic therapy of adrenocortical carcinoma (ACC) is limited by heterogeneous tumor response and adverse effects." | 1.43 | Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. ( Beuschlein, F; Fassnacht, M; Hantel, C; Igaz, P; Jung, S; Nagy, Z; Reincke, M; Weiss, M; Zambetti, G, 2016) |
| "Molecular characterization of adrenocortical cancer has deepened our understanding of this genetically complex disease while identifying subgroups whose importance remains to be determined." | 1.43 | Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters. ( Balasubramaniam, S; Bates, SE; Edgerly, M; Fojo, T; Leuva, H; Litman, T; Merino, MJ; Payabyab, EC; Velarde, M; Venkatesan, AM, 2016) |
| "Mitotane was administered in 12 (71 %) patients with stage III-IV ACCs with a 5-year survival rate 25 % compared to 20 % in patients who did not receive Mitotane." | 1.42 | Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm. ( Abdel-Aziz, TE; Mihai, R; Rajeev, P; Sadler, G; Weaver, A, 2015) |
| "We aimed at investigating in vitro the cytotoxic activity (determined using WST-1, apoptosis and cell cycle assays) of gemcitabine, alone or in combination with mitotane, in mitotane-sensitive H295R and mitotane-insensitive SW-13 cells." | 1.40 | Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. ( Berruti, A; Carturan, S; Germano, A; Lo Buono, N; Papotti, M; Rapa, I; Terzolo, M; Volante, M, 2014) |
| "Overt hypercortisolism was observed in 197 patients (37." | 1.40 | Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. ( Allolio, B; Ardito, A; Baudin, E; Berruti, A; Deutschbein, T; Else, T; Fassnacht, M; Feelders, R; Gelderblom, H; Grisanti, S; Haak, H; Hammer, GD; Kerkhofs, T; Kroiss, M; Leboulleux, S; Papotti, M; Porpiglia, F; Ronchi, C; Sperone, P; Terzolo, M; Volante, M; Williams, AR, 2014) |
| "Adrenocortical carcinoma is a rare malignant endocrine neoplasia." | 1.40 | Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. ( Else, T; Hammer, GD; Jolly, S; Miller, BS; Sabolch, A; Williams, AR, 2014) |
| "Mitotane treatment also led to decreased cortisol and DHEAS concentration in the culture media." | 1.39 | The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells. ( Jagodziński, PP; Lehmann, TP; Wrzesiński, T, 2013) |
| "The pregnancy was complicated by fetal exposure to mitotane and dexamethasone." | 1.37 | Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure. ( Burym, C; Cronin, CM; Kojori, F; Salamon, E; Sellers, EA, 2011) |
| "We report the first case of adrenocortical carcinoma secreting cortisol (Cushing's syndrome) and aldosterone (Conn's syndrome) with extensive distant metastasis at the time of diagnosis." | 1.37 | Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report. ( Bang, SM; Beom, SH; Choi, Y; Chung, JH; Kim, JH; Kim, YJ; Lee, JS; Lee, KW; Song, KH; Yang, Y, 2011) |
| "Median survival in stage II adrenocortical carcinoma (ACC) differs widely in published series ranging between 23 and more than 60 months." | 1.36 | Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. ( Agha, A; Allolio, B; Beuschlein, F; Fassnacht, M; Fenske, W; Führer, D; Hahner, S; Johanssen, S; Jurowich, C; Petersenn, S; Quinkler, M; Spahn, M; Weismann, D, 2010) |
| "In suspected nonmetastatic adrenocortical carcinoma (ACC) a careful preoperative diagnostic work up is needed including comprehensive endocrine analysis as recommended by the European Network for the Study of Adrenal Tumors (http://www." | 1.36 | What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? ( Allolio, B; Fassnacht, M, 2010) |
| "Drug therapy for adrenocortical carcinoma (ACC), a rare and lethal malignancy, is largely empirical and ineffective." | 1.35 | Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. ( Barlaskar, FM; Ben-Josef, E; Giordano, TJ; Hammer, GD; Heaton, JH; Kim, AC; Kuick, R; Spalding, AC; Thomas, DG, 2009) |
| "Cushing syndrome was diagnosed on the basis of a markedly elevated 24-hour urine free cortisol level and classic cushingoid features." | 1.35 | A patient with ectopic cortisol production derived from malignant testicular masses. ( Dluhy, RG; Jain, SH; Nosé, V; Sadow, PM, 2008) |
| "Establishing a database for adrenocortical carcinomas in the UK would contribute to our understanding of the management of this disease." | 1.35 | How is adrenocortical cancer being managed in the UK? ( Aspinall, SR; Bliss, RD; Harrison, BJ; Imisairi, AH; Lennard, TW; Scott-Coombes, D, 2009) |
| " Treatment resulted in an improvement of performance status and a reduction of the daily dosage of mitotane in all patients." | 1.35 | Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma. ( Bizzarri, G; Graziano, FM; Guglielmi, R; Pacella, CM; Pacella, S; Papini, E; Stasi, R, 2008) |
| "Local tumor recurrence is common in adrenocortical carcinoma (ACC) and is the most frequent cause for reoperation." | 1.33 | Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Flentje, M; Hahner, S; Kenn, W; Koschker, AC; Polat, B, 2006) |
| "Because of the rarity of adrenocortical carcinoma, survival rates and the prognosis for patients who have undergone operation are not well known." | 1.31 | Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. ( Andreassian, B; Carnaille, B; Chapuis, Y; Charpenay, C; Cougard, P; Goudet, P; Henry, JF; Icard, P; Proye, C, 2001) |
| "A 58-year-old man had adrenocortical carcinoma in the right adrenal gland." | 1.30 | Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999) |
| "We report here a new case of feminizing adrenocortical carcinoma revealed by a bilateral gynecomastia in a 50 year old man." | 1.29 | [Bilateral gynecomastia revealing malignant feminizing adrenocortical carcinoma]. ( Chraibi, A; Kadiri, A, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.17) | 18.7374 |
| 1990's | 9 (3.50) | 18.2507 |
| 2000's | 45 (17.51) | 29.6817 |
| 2010's | 128 (49.81) | 24.3611 |
| 2020's | 72 (28.02) | 2.80 |
| Authors | Studies |
|---|---|
| Lehmann, TP | 1 |
| Wrzesiński, T | 1 |
| Jagodziński, PP | 1 |
| Uchihara, M | 1 |
| Tanioka, M | 1 |
| Kojima, Y | 1 |
| Nishikawa, T | 1 |
| Sudo, K | 1 |
| Shimoi, T | 1 |
| Noguchi, E | 1 |
| Maeshima, AM | 1 |
| Yonemori, K | 1 |
| Grisanti, S | 14 |
| Cosentini, D | 11 |
| Laganà, M | 9 |
| Turla, A | 5 |
| Berruti, A | 32 |
| Bry-Gauillard, H | 2 |
| Belin, F | 1 |
| Vinolas, C | 1 |
| Renoult-Pierre, P | 1 |
| Massin, N | 1 |
| Young, J | 6 |
| Sifer, C | 1 |
| Grynberg, M | 1 |
| Abate, A | 4 |
| Rossini, E | 3 |
| Tamburello, M | 2 |
| Fiorentini, C | 2 |
| Tiberio, GAM | 3 |
| Scatolini, M | 1 |
| Grosso, E | 1 |
| Hantel, C | 7 |
| Memo, M | 2 |
| Sigala, S | 7 |
| Altieri, B | 6 |
| Lalli, E | 4 |
| Faggiano, A | 1 |
| Hadoux, J | 3 |
| Libè, R | 6 |
| Frigerio, M | 1 |
| Deschamps, F | 2 |
| Zamparini, M | 2 |
| Lamartina, L | 2 |
| Pedersini, R | 1 |
| Valsecchi, C | 1 |
| Maroldi, R | 1 |
| Al Ghuzlan, A | 6 |
| Terzolo, M | 36 |
| Gasparotti, R | 1 |
| Baudin, E | 20 |
| Haberbosch, L | 1 |
| Maurer, L | 1 |
| Sandforth, A | 1 |
| Wernicke, C | 1 |
| Spranger, J | 1 |
| Mai, K | 1 |
| Jumpertz von Schwartzenberg, R | 1 |
| Daher, M | 1 |
| Varghese, J | 2 |
| Gruschkus, SK | 1 |
| Jimenez, C | 1 |
| Waguespack, SG | 1 |
| Bedrose, S | 1 |
| Altameemi, L | 1 |
| Bazerbashi, H | 1 |
| Naing, A | 1 |
| Subaiah, V | 1 |
| Campbell, MT | 1 |
| Shah, AY | 1 |
| Zhang, M | 1 |
| Sheth, RA | 1 |
| Karam, JA | 1 |
| Wood, CG | 1 |
| Perrier, ND | 2 |
| Graham, PH | 1 |
| Lee, JE | 3 |
| Habra, MA | 3 |
| Strobbe, G | 1 |
| Fraipont, F | 1 |
| Raimbault, S | 1 |
| Mercier, S | 1 |
| Stala, T | 1 |
| Naveau, M | 1 |
| Villain, A | 1 |
| Sakji, I | 1 |
| Defachelles, AS | 1 |
| Feutry, F | 1 |
| Marliot, G | 1 |
| Ambrosini, R | 1 |
| Ferrari, VD | 3 |
| Gianoncelli, A | 1 |
| Canu, L | 6 |
| Lerario, AM | 3 |
| Mohan, DR | 1 |
| Hammer, GD | 8 |
| Cremaschi, V | 3 |
| Consoli, F | 1 |
| Fassnacht, M | 38 |
| Goodkin, DA | 1 |
| Ueda, S | 1 |
| Nakane, K | 1 |
| Namiki, S | 1 |
| Takeuchi, Y | 1 |
| Kawase, M | 1 |
| Takeuchi, S | 1 |
| Kawase, K | 1 |
| Nakai, C | 1 |
| Kato, D | 1 |
| Takai, M | 1 |
| Iinuma, K | 1 |
| Tsuchiya, T | 1 |
| Miyazaki, T | 1 |
| Koie, T | 1 |
| Warde, KM | 2 |
| Lim, YJ | 2 |
| Ribes Martinez, E | 2 |
| Beuschlein, F | 10 |
| O'Shea, P | 2 |
| Dennedy, MC | 2 |
| Kuhlen, M | 1 |
| Mier, P | 1 |
| Kunstreich, M | 1 |
| Lessel, L | 1 |
| Schneider, D | 1 |
| Brecht, I | 1 |
| Schewe, DM | 1 |
| Frühwald, MC | 1 |
| Vorwerk, P | 1 |
| Redlich, A | 1 |
| Cárdenas-Salas, J | 1 |
| Castelo, B | 1 |
| Regojo, RM | 1 |
| González-Sanchez, JA | 1 |
| Álvarez-Escolá, C | 2 |
| Ren, L | 1 |
| Yang, Y | 2 |
| Li, W | 1 |
| Zheng, X | 1 |
| Liu, J | 1 |
| Li, S | 1 |
| Yang, H | 1 |
| Zhang, Y | 1 |
| Ge, B | 1 |
| Zhang, S | 1 |
| Fu, W | 1 |
| Dong, D | 1 |
| Du, G | 1 |
| Wang, J | 1 |
| Tőke, J | 1 |
| Uhlyarik, A | 1 |
| Lohinszky, J | 1 |
| Stark, J | 1 |
| Huszty, G | 1 |
| Micsik, T | 1 |
| Borka, K | 1 |
| Reismann, P | 1 |
| Horányi, J | 1 |
| Igaz, P | 2 |
| Tóth, M | 1 |
| Sarvestani, AL | 1 |
| Gregory, SN | 1 |
| Teke, ME | 1 |
| Hernandez, JM | 1 |
| Padua, TC | 1 |
| Marandino, L | 1 |
| Raggi, D | 1 |
| Hallanger-Johnson, J | 1 |
| Kutikov, A | 1 |
| Spiess, PE | 1 |
| Necchi, A | 1 |
| Ilanchezhian, M | 3 |
| Varghese, DG | 3 |
| Glod, JW | 3 |
| Reilly, KM | 3 |
| Widemann, BC | 3 |
| Pommier, Y | 3 |
| Kaplan, RN | 3 |
| Del Rivero, J | 3 |
| Puglisi, S | 11 |
| Basile, V | 11 |
| Sperone, P | 8 |
| Brönimann, S | 3 |
| Garstka, N | 3 |
| Remzi, M | 3 |
| LaPensee, CR | 1 |
| Calabrese, A | 4 |
| Borin, C | 1 |
| Perotti, P | 10 |
| Pia, A | 5 |
| Berchialla, P | 4 |
| Volante, M | 9 |
| Fiori, C | 2 |
| Porpiglia, F | 7 |
| Veltri, A | 2 |
| Reimondo, G | 7 |
| Hassan, I | 1 |
| Sheikh, A | 1 |
| Tkachuk, AV | 1 |
| Beltsevich, DG | 1 |
| Porubayeva, EE | 1 |
| Urusova, LS | 1 |
| Mangone, A | 1 |
| Detomas, M | 1 |
| Prete, A | 1 |
| Abbas, H | 2 |
| Asia, M | 1 |
| Elhassan, YS | 1 |
| Mantovani, G | 1 |
| Ronchi, CL | 7 |
| Poirier, J | 2 |
| Godemel, S | 1 |
| Mourot, A | 1 |
| Grunenwald, S | 2 |
| Olney, HJ | 1 |
| Le, XK | 1 |
| Lacroix, A | 4 |
| Caron, P | 4 |
| Bourdeau, I | 3 |
| Kenney, L | 1 |
| Hughes, M | 1 |
| Pan, LH | 1 |
| Yen, CC | 1 |
| Huang, CJ | 1 |
| Ng, XN | 1 |
| Lin, LY | 1 |
| Ferraù, F | 1 |
| Violi, MA | 1 |
| Ceccato, F | 1 |
| Scaroni, C | 1 |
| Di Dalmazi, G | 1 |
| Stigliano, A | 5 |
| Loli, P | 4 |
| Pivonello, R | 2 |
| Arvat, E | 3 |
| Morelli, V | 1 |
| Urru, S | 1 |
| Cannavò, S | 1 |
| Delbarba, A | 1 |
| Facondo, P | 1 |
| Pezzaioli, LC | 1 |
| Alberti, A | 1 |
| Cappelli, C | 1 |
| Ferlin, A | 1 |
| Damilano, RA | 1 |
| Bergoglio, MT | 1 |
| Hescot, S | 7 |
| Debien, V | 1 |
| Drui, D | 2 |
| Haissaguerre, M | 3 |
| de la Fouchardiere, C | 3 |
| Vezzosi, D | 2 |
| Do Cao, C | 3 |
| Le Tourneau, C | 1 |
| Massard, C | 1 |
| du Rusquec, P | 1 |
| Oshiro, H | 2 |
| Shimizu, Y | 1 |
| Nakayasu, R | 1 |
| Utsunomiya, N | 1 |
| Son, C | 1 |
| Tsuji, K | 1 |
| Asai, S | 1 |
| Katsushima, H | 1 |
| Ishihara, M | 1 |
| Hashimoto, K | 1 |
| Kanamaru, S | 1 |
| Kastelan, D | 1 |
| Arlt, W | 3 |
| Haak, HR | 14 |
| Decoudier, B | 1 |
| Lasolle, H | 1 |
| Quinkler, M | 8 |
| Chabre, O | 1 |
| Giordano, R | 1 |
| Zatelli, MC | 2 |
| Bancos, I | 2 |
| Fragoso, MCBV | 3 |
| Luconi, M | 4 |
| Kroiss, M | 19 |
| Megerle, F | 4 |
| Hahner, S | 12 |
| Kimpel, O | 1 |
| Dusek, T | 1 |
| Nölting, S | 1 |
| Chortis, V | 2 |
| Ettaieb, MH | 2 |
| Bovis, F | 1 |
| Sormani, MP | 1 |
| Bruzzi, P | 2 |
| Bertherat, J | 4 |
| Cantini, G | 1 |
| Niccolai, E | 1 |
| Di Gloria, L | 1 |
| Baldi, S | 1 |
| Propato, AP | 1 |
| Fei, L | 1 |
| Nannini, G | 1 |
| Nesi, G | 1 |
| Ramazzotti, M | 1 |
| Amedei, A | 1 |
| Stadler, G | 1 |
| de Almeida Veiga, A | 1 |
| Rita Corso, C | 1 |
| Bach de Assis, C | 1 |
| de Toledo Nogueira, B | 1 |
| Regina Rocha Martins, L | 1 |
| Cruz Bonk, B | 1 |
| Lada Degaut Pontes, F | 1 |
| Cavalcante de Figueiredo, B | 1 |
| Mera de Souza, L | 1 |
| Weng, Y | 1 |
| Wang, L | 1 |
| Wang, XY | 1 |
| Fan, XX | 1 |
| Yan, L | 1 |
| Li, ZH | 1 |
| Zhang, SL | 1 |
| Nowak, KM | 2 |
| Łebek-Szatańska, A | 2 |
| Samsel, R | 2 |
| Roszkowska-Purska, K | 2 |
| Ćwikła, JB | 1 |
| Papierska, L | 2 |
| van Koetsveld, PM | 4 |
| Creemers, SG | 3 |
| Dogan, F | 1 |
| Franssen, GJH | 1 |
| de Herder, WW | 6 |
| Feelders, RA | 8 |
| Hofland, LJ | 5 |
| Haider, MS | 2 |
| Schreiner, J | 2 |
| Kendl, S | 5 |
| Luxenhofer, R | 2 |
| Belavgeni, A | 1 |
| Bornstein, SR | 2 |
| von Mässenhausen, A | 1 |
| Tonnus, W | 1 |
| Stumpf, J | 1 |
| Meyer, C | 1 |
| Othmar, E | 1 |
| Latk, M | 1 |
| Kanczkowski, W | 1 |
| Hugo, C | 1 |
| Ziegler, CG | 1 |
| Schally, AV | 1 |
| Krone, NP | 1 |
| Linkermann, A | 1 |
| Bronswijk, MJH | 1 |
| Laenen, A | 1 |
| Bechter, OE | 1 |
| Ando, M | 1 |
| Hirabatake, M | 1 |
| Yasui, H | 1 |
| Fukushima, S | 1 |
| Sugioka, N | 1 |
| Hashida, T | 1 |
| Yamashita, D | 1 |
| Hanai, T | 1 |
| Onuki, T | 1 |
| Suzuki, K | 1 |
| Nakayama, T | 1 |
| Germano, A | 3 |
| Rossin, D | 1 |
| Leoni, V | 1 |
| Iaia, N | 1 |
| Saba, L | 3 |
| Caccia, C | 1 |
| Poli, G | 2 |
| Biasi, F | 1 |
| Schoenmakers, E | 1 |
| Leonard, M | 1 |
| Lawless, SJ | 1 |
| Chatterjee, KV | 1 |
| Gurnell, M | 1 |
| Abrahamsson, G | 1 |
| Ekerhovd, E | 1 |
| Janson, PO | 1 |
| Jansson, S | 3 |
| Ahlman, H | 3 |
| Wängberg, B | 3 |
| Norström, A | 1 |
| Zancanella, P | 2 |
| Oliveira, DML | 1 |
| de Oliveira, BH | 1 |
| Woiski, TD | 1 |
| Pinto, CC | 1 |
| Santana, MHA | 1 |
| Souto, EB | 1 |
| Severino, P | 1 |
| Weigand, I | 3 |
| Lacombe, AMF | 1 |
| Kircher, S | 1 |
| Landwehr, LS | 1 |
| Zerbini, MCN | 1 |
| Paiva, I | 2 |
| Della Casa, S | 1 |
| Sbiera, S | 7 |
| Trotta, F | 1 |
| Avena, P | 1 |
| Chimento, A | 1 |
| Rago, V | 1 |
| De Luca, A | 1 |
| Sculco, S | 1 |
| Nocito, MC | 1 |
| Malivindi, R | 1 |
| Fallo, F | 1 |
| Pezzani, R | 1 |
| Pilon, C | 1 |
| Lasorsa, FM | 1 |
| Barile, SN | 1 |
| Palmieri, L | 1 |
| Pezzi, V | 1 |
| Casaburi, I | 1 |
| Sirianni, R | 1 |
| Yin, A | 1 |
| Ettaieb, MHT | 2 |
| Swen, JJ | 1 |
| van Deun, L | 1 |
| Kerkhofs, TMA | 2 |
| van der Straaten, RJHM | 1 |
| Corssmit, EPM | 1 |
| Gelderblom, H | 8 |
| Kerstens, MN | 1 |
| Eekhoff, M | 1 |
| Timmers, HJLM | 1 |
| D'Avolio, A | 2 |
| Cusato, J | 2 |
| Guchelaar, HJ | 4 |
| Moes, DJAR | 1 |
| Mirsharifi, A | 1 |
| Vasei, M | 1 |
| Sadeghian, E | 1 |
| Ghorbani-Abdehgah, A | 1 |
| Naybandi Atashi, S | 1 |
| Salle, L | 1 |
| Mas, R | 1 |
| Teissier-Clément, MP | 1 |
| Vikner, ME | 1 |
| Krogh, J | 1 |
| Daugaard, G | 1 |
| Andreassen, M | 1 |
| Liu, X | 1 |
| Fu, Q | 1 |
| Tang, Y | 2 |
| Deng, JH | 1 |
| Mei, D | 1 |
| Zhang, B | 1 |
| Loewe, R | 1 |
| Rogowski-Lehmann, N | 1 |
| Pfluger, T | 1 |
| Reincke, M | 4 |
| Bluemel, C | 2 |
| De Filpo, G | 1 |
| Mannelli, M | 5 |
| Corso, CR | 1 |
| Acco, A | 1 |
| Bach, C | 1 |
| Bonatto, SJR | 2 |
| de Figueiredo, BC | 1 |
| de Souza, LM | 1 |
| Bansari, A | 1 |
| Radhakrishnan, NS | 1 |
| Kattan, JN | 1 |
| Rodriguez-Galindo, C | 1 |
| Krailo, MD | 1 |
| Pinto, EM | 1 |
| Pashankar, F | 1 |
| Weldon, CB | 1 |
| Huang, L | 1 |
| Caran, EM | 1 |
| Hicks, J | 1 |
| McCarville, MB | 1 |
| Malkin, D | 1 |
| Wasserman, JD | 1 |
| de Oliveira Filho, AG | 1 |
| LaQuaglia, MP | 1 |
| Ward, DA | 1 |
| Zambetti, G | 2 |
| Mastellaro, MJ | 1 |
| Pappo, AS | 1 |
| Ribeiro, RC | 1 |
| Kiseljak-Vassiliades, K | 1 |
| Hamrahian, A | 1 |
| Habra, M | 1 |
| Vaidya, A | 1 |
| Levine, AC | 1 |
| Else, T | 6 |
| Steenaard, RV | 1 |
| Goyzueta Mamani, LD | 1 |
| de Carvalho, JC | 1 |
| Tanobe, VAO | 1 |
| Soccol, CR | 1 |
| Carminati, O | 1 |
| Rosti, G | 1 |
| Boilève, A | 1 |
| Mathy, E | 1 |
| Roux, C | 1 |
| Faron, M | 1 |
| Tselikas, L | 1 |
| Leboulleux, S | 12 |
| de Baere, T | 2 |
| Ohmoto, A | 1 |
| Shigematsu, Y | 1 |
| Fukuda, N | 1 |
| Wang, X | 1 |
| Urasaki, T | 1 |
| Hayashi, N | 1 |
| Sato, Y | 1 |
| Nakano, K | 1 |
| Yunokawa, M | 1 |
| Ono, M | 1 |
| Komai, Y | 1 |
| Numao, N | 1 |
| Yuasa, T | 1 |
| Yonese, J | 1 |
| Tomomatsu, J | 1 |
| Inamura, K | 1 |
| Takahashi, S | 1 |
| Ahmad, T | 1 |
| Groll, J | 1 |
| Scherf-Clavel, O | 1 |
| Pulzer, A | 3 |
| Claps, M | 3 |
| Daffara, F | 6 |
| Boscaro, M | 1 |
| Tiberio, G | 1 |
| Zaggia, B | 3 |
| Borges, KS | 1 |
| Andrade, AF | 1 |
| Silveira, VS | 1 |
| Marco Antonio, DS | 1 |
| Vasconcelos, EJR | 1 |
| Antonini, SRR | 1 |
| Tone, LG | 1 |
| Scrideli, CA | 1 |
| Waszut, U | 1 |
| Szyszka, P | 1 |
| Dworakowska, D | 1 |
| Reidy-Lagunes, DL | 1 |
| Lung, B | 1 |
| Untch, BR | 1 |
| Raj, N | 1 |
| Hrabovsky, A | 1 |
| Kelly, C | 1 |
| Gerst, S | 1 |
| Katz, S | 1 |
| Kampel, L | 1 |
| Chou, J | 1 |
| Gopalan, A | 1 |
| Saltz, LB | 1 |
| Taza, F | 1 |
| Chovanec, M | 1 |
| Hahn, N | 1 |
| Albany, C | 1 |
| Cabezón-Gutiérrez, L | 1 |
| Khosravi-Shahi, P | 1 |
| Custodio-Cabello, S | 1 |
| Lujan-Rodríguez, DR | 1 |
| Garijo-Álvarez, JÁ | 1 |
| Causso-Lariena, CM | 1 |
| Franco-Moreno, AI | 1 |
| De Francia, S | 4 |
| Allegra, S | 1 |
| Carrella, S | 1 |
| Pirro, E | 1 |
| Piccione, FM | 1 |
| De Martino, F | 1 |
| Ferrero, A | 2 |
| Daffara, FC | 1 |
| Di Carlo, F | 1 |
| Tampellini, M | 1 |
| Cerri, S | 1 |
| Lazzari, B | 1 |
| Ferrari, V | 1 |
| Roca, E | 2 |
| Bongard, V | 1 |
| Illouz, F | 1 |
| Borson-Chazot, F | 1 |
| Djobo, B | 1 |
| Berdelou, A | 2 |
| Tabarin, A | 3 |
| Schlumberger, M | 6 |
| Briet, C | 1 |
| Pape, E | 1 |
| Feliu, C | 1 |
| Yéléhé-Okouma, M | 1 |
| Colling, N | 1 |
| Djerada, Z | 1 |
| Gambier, N | 1 |
| Weryha, G | 1 |
| Scala-Bertola, J | 1 |
| Szkodziak, PR | 1 |
| Czuczwar, P | 1 |
| Woźniak, S | 1 |
| Szkodziak, F | 1 |
| Paszkowski, T | 1 |
| Herrmann, W | 1 |
| Schloetelburg, W | 1 |
| Ruggiero, C | 1 |
| Doghman-Bouguerra, M | 2 |
| Ronco, C | 1 |
| Benhida, R | 1 |
| Rocchi, S | 1 |
| Cichocki, A | 1 |
| Ambroziak, U | 1 |
| Koperski, Ł | 1 |
| Otto, M | 1 |
| Zgliczyński, W | 1 |
| Rapa, I | 2 |
| Shuayb, M | 1 |
| Das, A | 1 |
| Uddin, MN | 1 |
| Liu, Z | 1 |
| Zou, Z | 1 |
| Liang, J | 1 |
| Lu, Y | 1 |
| Zhu, Y | 2 |
| Arshad, U | 1 |
| Taubert, M | 1 |
| Kurlbaum, M | 2 |
| Frechen, S | 1 |
| Herterich, S | 1 |
| Hamacher, S | 1 |
| Fuhr, U | 1 |
| Farooq, AU | 1 |
| Amjad, W | 1 |
| Kochar, T | 1 |
| Adhikari, S | 1 |
| Dickson, PV | 1 |
| Kim, L | 1 |
| Yen, TWF | 1 |
| Yang, A | 1 |
| Grubbs, EG | 2 |
| Patel, D | 1 |
| Solórzano, CC | 2 |
| Dekkers, OM | 1 |
| de Krijger, R | 1 |
| Mihai, R | 4 |
| Assie, G | 1 |
| Sbiera, I | 3 |
| Fragni, M | 1 |
| Fisogni, S | 1 |
| Vezzoli, S | 1 |
| Bonini, SA | 1 |
| Dalmiglio, C | 1 |
| Salvi, V | 1 |
| Bosisio, D | 1 |
| Missale, C | 1 |
| Facchetti, F | 1 |
| Almeida, MQ | 1 |
| Bezerra-Neto, JE | 1 |
| Mendonça, BB | 1 |
| Latronico, AC | 1 |
| Di Paolo, A | 1 |
| Ciofi, L | 1 |
| Bacca, A | 1 |
| Bernini, G | 1 |
| Boulate, G | 1 |
| Amazit, L | 1 |
| Naman, A | 1 |
| Seck, A | 3 |
| Paci, A | 6 |
| Lombes, A | 1 |
| Pussard, E | 1 |
| Lombes, M | 4 |
| Khan, MS | 1 |
| Ali, A | 1 |
| Tariq, I | 1 |
| Khan, MA | 1 |
| Bakar, MA | 1 |
| Anwar, AW | 1 |
| Komarowska, H | 1 |
| Ruciński, M | 1 |
| Fichna, M | 1 |
| Bromińska, B | 1 |
| Iżycki, D | 1 |
| Czarnywojtek, A | 1 |
| Ruchała, M | 1 |
| Tierney, JF | 1 |
| Chivukula, SV | 1 |
| Pappas, SG | 1 |
| Schadde, E | 1 |
| Hertl, M | 1 |
| Kebebew, E | 1 |
| Keutgen, X | 1 |
| Freire, DS | 1 |
| Siqueira, SA | 1 |
| Zerbini, MC | 1 |
| Wajchenberg, BL | 1 |
| Corrêa-Giannella, ML | 1 |
| Lucon, AM | 1 |
| Pereira, MA | 1 |
| Vitale, G | 1 |
| Waaijers, M | 1 |
| Sprij-Mooij, DM | 1 |
| de Krijger, RR | 2 |
| Speel, EJ | 1 |
| Hofland, J | 1 |
| Lamberts, SW | 2 |
| Hermsen, IG | 3 |
| Kerkhofs, TM | 4 |
| Wilmink, H | 2 |
| Smit, JW | 1 |
| de Miranda, NF | 1 |
| van Eijk, R | 1 |
| van Wezel, T | 1 |
| Morreau, H | 1 |
| Baudin, AE | 1 |
| Ardito, A | 3 |
| deVries, JH | 1 |
| Allolio, B | 18 |
| Doghman, M | 1 |
| Lo Buono, N | 1 |
| Carturan, S | 1 |
| Papotti, M | 5 |
| Chadarevian, R | 3 |
| Mueller, HH | 1 |
| Skogseid, B | 3 |
| Mantero, F | 5 |
| Haak, H | 3 |
| Kerkhofs, T | 1 |
| Williams, AR | 3 |
| Deutschbein, T | 3 |
| Feelders, R | 1 |
| Ronchi, C | 1 |
| Sabolch, A | 1 |
| Jolly, S | 1 |
| Miller, BS | 1 |
| Jung, S | 3 |
| Mussack, T | 2 |
| FISHER, DA | 1 |
| PANOS, TC | 1 |
| MELBY, JC | 1 |
| Manenschijn, L | 1 |
| van Rossum, EF | 1 |
| Allasino, B | 1 |
| Worden, FP | 1 |
| Ramm, CA | 1 |
| Hesseltine, EA | 1 |
| Hasseltine, EA | 1 |
| Stadler, WM | 1 |
| Shah, MH | 1 |
| Agamah, E | 1 |
| Rao, K | 1 |
| Derijks, LJ | 2 |
| Ettaieb, H | 1 |
| den Hartigh, J | 4 |
| Neef, K | 1 |
| Slama, A | 1 |
| Viengchareun, S | 1 |
| Trabado, S | 1 |
| Brailly-Tabard, S | 1 |
| Gagliano, T | 1 |
| Gentilin, E | 1 |
| Benfini, K | 1 |
| Di Pasquale, C | 1 |
| Tassinari, M | 1 |
| Falletta, S | 1 |
| Feo, C | 1 |
| Tagliati, F | 1 |
| Uberti, ED | 1 |
| Pal, SK | 1 |
| Gartrell, B | 1 |
| Olsson, CA | 1 |
| Stein, CA | 1 |
| Steinhauer, S | 1 |
| Scott-Wild, V | 1 |
| Bala, M | 2 |
| Eekhoff, EM | 1 |
| Neef, C | 1 |
| Sasano, H | 2 |
| Satoh, F | 1 |
| Nakamura, Y | 1 |
| Tada, H | 1 |
| Nohara, A | 1 |
| Kawashiri, MA | 1 |
| Inazu, A | 1 |
| Mabuchi, H | 1 |
| Yamagishi, M | 1 |
| Salenave, S | 1 |
| Bernard, V | 1 |
| Guignat, L | 1 |
| Bachelot, A | 1 |
| Droumaguet, C | 1 |
| Pierre, P | 1 |
| Crinière, L | 1 |
| Santulli, P | 1 |
| Touraine, P | 1 |
| Chanson, P | 3 |
| Maiter, D | 2 |
| Abdel-Aziz, TE | 1 |
| Rajeev, P | 1 |
| Sadler, G | 1 |
| Weaver, A | 1 |
| Ranvier, GG | 1 |
| Inabnet, WB | 1 |
| Guerin, M | 1 |
| Cockenpot, F | 1 |
| Huby, T | 1 |
| Broutin, S | 1 |
| Baur, J | 1 |
| Schedelbeck, U | 1 |
| Wild, V | 1 |
| Steger, U | 1 |
| Leich, E | 1 |
| Liebisch, G | 1 |
| Schirbel, A | 2 |
| Wiemer, L | 1 |
| Matysik, S | 1 |
| Eckhardt, C | 1 |
| Gardill, F | 1 |
| Gehl, A | 1 |
| Schmitz, G | 1 |
| Rosenwald, A | 1 |
| Zhuang, J | 1 |
| Wang, D | 1 |
| Wu, R | 1 |
| Tu, X | 1 |
| Chen, Y | 1 |
| Qiu, S | 1 |
| Mayor-Ibarguren, A | 1 |
| Roldán-Puchalt, MC | 1 |
| Gómez-Fernández, C | 1 |
| Albízuri-Prado, F | 1 |
| Korpershoek, E | 2 |
| Franssen, GJ | 2 |
| van Kemenade, FJ | 2 |
| De Martino, MC | 1 |
| Colao, A | 1 |
| Plonné, D | 1 |
| Schirmer, D | 1 |
| Zink, M | 1 |
| Lapa, C | 1 |
| Klinker, H | 1 |
| Heinz, W | 1 |
| Xu, Y | 1 |
| Dong, B | 1 |
| Huang, J | 1 |
| Kong, W | 1 |
| Xue, W | 1 |
| Zhang, J | 1 |
| Huang, Y | 1 |
| Postlewait, LM | 1 |
| Ethun, CG | 1 |
| Tran, TB | 1 |
| Prescott, JD | 1 |
| Pawlik, TM | 1 |
| Wang, TS | 1 |
| Glenn, J | 1 |
| Hatzaras, I | 1 |
| Shenoy, R | 1 |
| Phay, JE | 1 |
| Keplinger, K | 1 |
| Fields, RC | 1 |
| Jin, LX | 1 |
| Weber, SM | 1 |
| Salem, A | 1 |
| Sicklick, JK | 1 |
| Gad, S | 1 |
| Yopp, AC | 1 |
| Mansour, JC | 1 |
| Duh, QY | 1 |
| Seiser, N | 1 |
| Kiernan, CM | 1 |
| Votanopoulos, KI | 1 |
| Levine, EA | 1 |
| Staley, CA | 1 |
| Poultsides, GA | 1 |
| Maithel, SK | 1 |
| Guelho, D | 1 |
| Vieira, A | 1 |
| Carrilho, F | 1 |
| El Ghorayeb, N | 1 |
| Rondeau, G | 1 |
| Latour, M | 1 |
| Cohade, C | 1 |
| Olney, H | 1 |
| Perrotte, P | 1 |
| Sabourin, A | 1 |
| Mazzuco, TL | 1 |
| Bex, M | 1 |
| Vroonen, L | 1 |
| T'Sjoen, G | 1 |
| Gil, T | 1 |
| Banh, C | 1 |
| Joppi, R | 1 |
| Gerardi, C | 1 |
| Bertele', V | 1 |
| Garattini, S | 1 |
| Granatiero, V | 1 |
| Lacas-Gervais, S | 1 |
| Brau, F | 1 |
| Rizzuto, R | 1 |
| Nagy, Z | 1 |
| Weiss, M | 1 |
| van den Dungen, ES | 1 |
| Dralle, H | 3 |
| Wahab, NA | 1 |
| Zainudin, S | 1 |
| AbAziz, A | 1 |
| Mustafa, N | 1 |
| Sukor, N | 1 |
| Kamaruddin, NA | 1 |
| Payabyab, EC | 1 |
| Balasubramaniam, S | 2 |
| Edgerly, M | 2 |
| Velarde, M | 1 |
| Merino, MJ | 1 |
| Venkatesan, AM | 1 |
| Leuva, H | 1 |
| Litman, T | 1 |
| Bates, SE | 1 |
| Fojo, T | 5 |
| Shapiro, I | 1 |
| Chiapponi, C | 1 |
| Bidlingmaier, M | 1 |
| Caramella, C | 1 |
| Cerquetti, L | 3 |
| Bucci, B | 3 |
| Marchese, R | 2 |
| Misiti, S | 3 |
| De Paula, U | 2 |
| Miceli, R | 1 |
| Muleti, A | 1 |
| Amendola, D | 2 |
| Piergrossi, P | 2 |
| Brunetti, E | 3 |
| Toscano, V | 3 |
| Advani, A | 1 |
| Vaikkakara, S | 1 |
| Gill, MS | 1 |
| Arun, CS | 1 |
| Pearce, SH | 1 |
| Ball, SG | 1 |
| James, RA | 1 |
| Lennard, TW | 2 |
| Bliss, RD | 2 |
| Quinton, R | 1 |
| Johnson, SJ | 1 |
| Fareau, GG | 1 |
| Lopez, A | 1 |
| Stava, C | 1 |
| Vassilopoulou-Sellin, R | 2 |
| Dogliotti, L | 3 |
| Angeli, A | 3 |
| Arai, H | 1 |
| Rino, Y | 1 |
| Yamanaka, S | 2 |
| Yukawa, N | 1 |
| Wada, N | 1 |
| Kato, H | 1 |
| Yanagimachi, M | 1 |
| Goto, H | 1 |
| Inayama, Y | 1 |
| Lee, J | 1 |
| Masuda, M | 1 |
| Barlaskar, FM | 1 |
| Spalding, AC | 1 |
| Heaton, JH | 1 |
| Kuick, R | 1 |
| Kim, AC | 1 |
| Thomas, DG | 1 |
| Giordano, TJ | 1 |
| Ben-Josef, E | 1 |
| Jain, SH | 1 |
| Sadow, PM | 1 |
| Nosé, V | 1 |
| Dluhy, RG | 1 |
| Patalano, A | 1 |
| Brancato, V | 1 |
| Alexandraki, KI | 1 |
| Kaltsas, GA | 1 |
| le Roux, CW | 1 |
| Ajodha, S | 1 |
| Christ-Crain, M | 1 |
| Akker, SA | 1 |
| Drake, WM | 1 |
| Edwards, R | 1 |
| Grossman, AB | 1 |
| Aspinall, SR | 1 |
| Imisairi, AH | 1 |
| Scott-Coombes, D | 1 |
| Harrison, BJ | 1 |
| Chalasani, S | 1 |
| Vats, HS | 1 |
| Banerjee, TK | 1 |
| McKenzie, AK | 1 |
| Strosberg, JR | 1 |
| Doherty, GM | 1 |
| Veytsman, I | 1 |
| Nieman, L | 1 |
| Attivi, D | 1 |
| Ajana, I | 1 |
| Astier, A | 1 |
| Demoré, B | 1 |
| Gibaud, S | 1 |
| Callender, GG | 1 |
| Xing, Y | 1 |
| Evans, DB | 1 |
| Phan, AT | 1 |
| Khorram-Manesh, A | 2 |
| Nilsson, B | 1 |
| Nilsson, O | 2 |
| Jakobsson, CE | 1 |
| Lindstedt, S | 2 |
| Odén, A | 1 |
| Hammer, G | 1 |
| Malandrino, P | 1 |
| Castaing, M | 1 |
| Caillou, B | 1 |
| Travagli, JP | 1 |
| Elias, D | 1 |
| Dromain, C | 1 |
| Sampaoli, C | 1 |
| Raza, G | 1 |
| Johanssen, S | 3 |
| Fenske, W | 1 |
| Weismann, D | 2 |
| Agha, A | 1 |
| Führer, D | 1 |
| Jurowich, C | 1 |
| Petersenn, S | 1 |
| Spahn, M | 1 |
| Sane, T | 1 |
| Cavlan, D | 1 |
| Bharwani, N | 1 |
| Grossman, A | 1 |
| van Erp, NP | 2 |
| Ploeger, BA | 1 |
| Romijn, JA | 1 |
| Hartigh, Jd | 1 |
| Houterman, S | 1 |
| Baszko-Błaszyk, D | 1 |
| Ochmańska, K | 1 |
| Waśko, R | 1 |
| Sowiński, J | 1 |
| Leblond, P | 1 |
| Delebarre, M | 1 |
| Aubert, S | 1 |
| Kojori, F | 1 |
| Cronin, CM | 1 |
| Salamon, E | 1 |
| Burym, C | 1 |
| Sellers, EA | 1 |
| Gahan, J | 1 |
| Shirodkar, SP | 1 |
| Gorin, MA | 1 |
| Salerno, TA | 1 |
| Ciancio, G | 1 |
| Zini, L | 1 |
| Lutz, WK | 1 |
| Costa, R | 1 |
| Wesolowski, R | 1 |
| Raghavan, D | 1 |
| Bellini, E | 1 |
| Saini, A | 1 |
| Beom, SH | 1 |
| Lee, KW | 1 |
| Choi, Y | 1 |
| Song, KH | 1 |
| Kim, YJ | 1 |
| Kim, JH | 1 |
| Bang, SM | 1 |
| Chung, JH | 1 |
| Lee, JS | 1 |
| Mauclère-Denost, S | 1 |
| Borget, I | 1 |
| Deandreis, D | 1 |
| Drouard, L | 1 |
| Demeure, MJ | 3 |
| Bussey, KJ | 2 |
| Kirschner, LS | 2 |
| Mornar, A | 1 |
| Sertić, M | 1 |
| Turk, N | 1 |
| Nigović, B | 1 |
| Koršić, M | 1 |
| Lin, CW | 1 |
| Chang, YH | 1 |
| Pu, HF | 1 |
| Welin, S | 1 |
| Schade-Brittinger, C | 1 |
| Jarzab, B | 1 |
| Sorbye, H | 1 |
| Torpy, DJ | 1 |
| Stepan, V | 1 |
| Schteingart, DE | 2 |
| Sundin, A | 1 |
| Hermsen, I | 1 |
| Willenberg, HS | 2 |
| Sender, M | 1 |
| Kenn, W | 2 |
| Müller, HH | 2 |
| Lankheet, N | 1 |
| Pöllinger, A | 1 |
| Laubner, K | 1 |
| Strasburger, CJ | 1 |
| Bapat, AA | 1 |
| Menaa, F | 1 |
| Menaa, B | 1 |
| Pentheroudakis, G | 1 |
| Ederhy, S | 1 |
| Cohen, A | 1 |
| Dufaitre, G | 1 |
| Chaderevian, R | 1 |
| Bertagna, X | 3 |
| Taylor, AE | 1 |
| Schneider, P | 1 |
| Tomlinson, JW | 1 |
| Hughes, BA | 1 |
| O'Neil, DM | 1 |
| Karavitaki, N | 1 |
| Opocher, G | 1 |
| Porfiri, E | 1 |
| Sherlock, M | 1 |
| Nightingale, P | 1 |
| Shackleton, CH | 1 |
| Stewart, PM | 1 |
| Tripto-Shkolnik, L | 1 |
| Blumenfeld, Z | 1 |
| Bronshtein, M | 1 |
| Salmon, A | 1 |
| Jaffe, A | 1 |
| MONTGOMERY, DA | 1 |
| WELBOURN, RB | 1 |
| MOLNAR, GD | 1 |
| NUNN, SL | 1 |
| TAUXE, WN | 1 |
| Kvacheniuk, AM | 1 |
| Iihara, M | 1 |
| Obara, T | 1 |
| Yoshimasu, T | 1 |
| Oura, S | 1 |
| Hirai, I | 1 |
| Kokawa, Y | 1 |
| Nishida, M | 1 |
| Sasaki, R | 1 |
| Tanino, H | 1 |
| Sakurai, T | 1 |
| Okamura, Y | 1 |
| Inagaki, T | 1 |
| Kodama, Y | 1 |
| Shinke, T | 1 |
| Tupikowski, W | 1 |
| Bednarek-Tupikowska, G | 1 |
| Florczak, A | 1 |
| Brauckhoff, M | 1 |
| Bacchetta, J | 1 |
| Droz, JP | 1 |
| Roman, S | 1 |
| Suzuki, T | 1 |
| Papewalis, C | 1 |
| Domberg, J | 1 |
| Fenk, R | 1 |
| Rohr, UP | 1 |
| Schinner, S | 1 |
| Scherbaum, WA | 1 |
| Schott, M | 1 |
| Polat, B | 1 |
| Koschker, AC | 3 |
| Flentje, M | 1 |
| Pianovski, MA | 1 |
| Oliveira, BH | 1 |
| Ferman, S | 1 |
| Piovezan, GC | 1 |
| Lichtvan, LL | 1 |
| Voss, SZ | 1 |
| Stinghen, ST | 1 |
| Callefe, LG | 1 |
| Parise, GA | 1 |
| Santana, MH | 1 |
| Figueiredo, BC | 1 |
| Lecka, A | 1 |
| Ginalska-Malinowska, M | 1 |
| van Ditzhuijsen, CI | 1 |
| van de Weijer, R | 1 |
| Pacella, CM | 1 |
| Stasi, R | 1 |
| Bizzarri, G | 1 |
| Pacella, S | 1 |
| Graziano, FM | 1 |
| Guglielmi, R | 1 |
| Papini, E | 1 |
| Tauchmanova, L | 1 |
| Conton, PA | 1 |
| Rossetto, R | 1 |
| Buci, L | 1 |
| Grossrubatscher, E | 1 |
| Bollito, E | 1 |
| Saeger, W | 1 |
| Ambrosi, B | 1 |
| Lombardi, G | 1 |
| Carmona-Bayonas, A | 1 |
| Soler, IO | 1 |
| Gómez, FI | 1 |
| Billalabeitia, EG | 1 |
| Saura, HP | 1 |
| Tafalla, MS | 1 |
| Díaz, MP | 1 |
| Coste, J | 1 |
| Machens, A | 1 |
| Dickstein, G | 1 |
| Shechner, C | 1 |
| Nativ, O | 1 |
| Brix, D | 1 |
| Riedmiller, H | 1 |
| Borro, M | 1 |
| Gentile, G | 1 |
| Simmaco, M | 1 |
| Ozimek, A | 1 |
| Diebold, J | 1 |
| Linke, R | 1 |
| Heyn, J | 1 |
| Hallfeldt, K | 1 |
| Kasperlik-Załuska, AA | 2 |
| Migdalska, BM | 2 |
| Zgliczyński, S | 1 |
| Makowska, AM | 2 |
| Kadiri, A | 1 |
| Chraibi, A | 1 |
| Guinee, VF | 1 |
| Hermans, J | 1 |
| van de Velde, CJ | 1 |
| Lentjes, EG | 1 |
| Goslings, BM | 1 |
| Fleuren, GJ | 1 |
| Krans, HM | 1 |
| Wooten, MD | 1 |
| King, DK | 1 |
| Somberg, LB | 1 |
| Williamson, SK | 1 |
| Lew, D | 1 |
| Miller, GJ | 1 |
| Balcerzak, SP | 1 |
| Baker, LH | 1 |
| Crawford, ED | 1 |
| Seki, M | 1 |
| Nomura, K | 1 |
| Hirohara, D | 1 |
| Kanazawa, M | 1 |
| Sawada, T | 1 |
| Takasaki, K | 1 |
| Demura, H | 1 |
| Heilmann, P | 1 |
| Wagner, P | 1 |
| Nawroth, PP | 1 |
| Ziegler, R | 1 |
| Icard, P | 1 |
| Goudet, P | 1 |
| Charpenay, C | 1 |
| Andreassian, B | 1 |
| Carnaille, B | 1 |
| Chapuis, Y | 1 |
| Cougard, P | 1 |
| Henry, JF | 1 |
| Proye, C | 1 |
| Jacobsson, CE | 1 |
| Syme, HM | 1 |
| Scott-Moncrieff, JC | 1 |
| Treadwell, NG | 1 |
| Thompson, MF | 1 |
| Snyder, PW | 1 |
| White, MR | 1 |
| Oliver, JW | 1 |
| Ichikawa, T | 1 |
| Ito, H | 1 |
| Abraham, J | 1 |
| Bakke, S | 1 |
| Rutt, A | 1 |
| Meadows, B | 1 |
| Merino, M | 1 |
| Alexander, R | 1 |
| Schrump, D | 1 |
| Bartlett, D | 1 |
| Choyke, P | 1 |
| Robey, R | 1 |
| Hung, E | 1 |
| Steinberg, SM | 1 |
| Bates, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma[NCT05344027] | 35 participants (Actual) | Observational | 2022-04-11 | Completed | |||
| Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines[NCT03257891] | Phase 2 | 25 participants (Anticipated) | Interventional | 2018-01-25 | Recruiting | ||
| Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry[NCT00453674] | 1,000 participants (Anticipated) | Observational | 2003-01-31 | Recruiting | |||
| Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism[NCT05255900] | 20 participants (Anticipated) | Observational | 2022-04-28 | Recruiting | |||
| Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane (EDP-M) in Patients With Advanced Adrenocortical Carcinoma (ACC)[NCT05913427] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-06-08 | Recruiting | ||
| Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence[NCT03723941] | Phase 3 | 240 participants (Anticipated) | Interventional | 2018-07-01 | Recruiting | ||
| Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma[NCT03145285] | Phase 2 | 10 participants (Anticipated) | Interventional | 2017-04-18 | Active, not recruiting | ||
| Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma[NCT02015026] | 67 participants (Actual) | Observational | 2013-12-13 | Completed | |||
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)[NCT06141369] | 21 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment[NCT00094497] | Phase 3 | 304 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy[NCT00453895] | Phase 2 | 39 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence[NCT00777244] | Phase 3 | 200 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy[NCT00786110] | Phase 2 | 30 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
scale ranged from 0 to 100 with higher score meaning greater quality of life (NCT00094497)
Timeframe: baseline and 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| EDP-M | -6.0 |
| Sz-M | -7.7 |
complete response or disease-free by time of surgery (NCT00094497)
Timeframe: every 8 weeks until progression (up to 5 years)
| Intervention | participants (Number) |
|---|---|
| EDP-M | 6 |
| Sz-M | 3 |
participants who died among those randomized to first-line therapy (NCT00094497)
Timeframe: every 8 weeks until death up to 5 years
| Intervention | participants (Number) |
|---|---|
| EDP-M | 108 |
| Sz-M | 124 |
(NCT00094497)
Timeframe: every 8 weeks until progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| EDP-M | 5.0 |
| Sz-M | 2.1 |
RECIST 1.0 was used to evaluate response (NCT00094497)
Timeframe: every 8 weeks up to 5 years
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| complete response | disease-free by time of surgery | partial response | stable disease | progressive disease | did not receive treatment | could not be evaluated | |
| EDP-M | 2 | 4 | 29 | 53 | 43 | 3 | 17 |
| Sz-M | 1 | 2 | 11 | 34 | 88 | 4 | 13 |
Clinical benefit was defined as stable disease or better for at least 12 weeks (NCT00453895)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Sunitinib | 5 |
Objective Response Rate defined by RECIST 1.0 (NCT00453895)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Sunitinib | 0 |
Overall Survival was defined as time from start of treatment until death or last follow-up. (NCT00453895)
Timeframe: up to 36 months
| Intervention | monhts (Median) |
|---|---|
| Sunitinib | 5.4 |
Progression-free survival is defined as time of start of study until documentation of Progress. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT00453895)
Timeframe: up to 400 days
| Intervention | days (Median) |
|---|---|
| Sunitinib | 83 |
Adverse events were rated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (see http://ctep.cancer.gov/reporting/ctc.html). (NCT00453895)
Timeframe: up to 400 days
| Intervention | number of adverse events/patient (Median) |
|---|---|
| Sunitinib | 4 |
63 reviews available for mitotane and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2022 |
ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Humans; | 2022 |
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined C | 2022 |
A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2023 |
Pediatric adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito | 2022 |
Pediatric adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito | 2022 |
Pediatric adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito | 2022 |
Pediatric adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito | 2022 |
Pediatric adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito | 2022 |
Pediatric adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito | 2022 |
Pediatric adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito | 2022 |
Pediatric adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito | 2022 |
Pediatric adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito | 2022 |
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro | 2023 |
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro | 2023 |
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro | 2023 |
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro | 2023 |
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro | 2023 |
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro | 2023 |
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro | 2023 |
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro | 2023 |
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro | 2023 |
Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Immunotherapy; Medical Oncology; Mitotan | 2023 |
Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Immunotherapy; Medical Oncology; Mitotan | 2023 |
Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Immunotherapy; Medical Oncology; Mitotan | 2023 |
Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Immunotherapy; Medical Oncology; Mitotan | 2023 |
Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Hypothy | 2023 |
Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2023 |
New perspectives for mitotane treatment of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic | 2020 |
Next-generation therapies for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Adrenocortical carcinoma: current treatment options.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2021 |
Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Agents, Ho | 2021 |
American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach.
Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Adult; Humans; Mitotane | 2020 |
How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Computer Simula | 2021 |
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Biolog | 2021 |
Understanding mitotane mode of action.
Topics: Adrenal Cortex; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Cell | 2017 |
[Palliative chemotherapy in metastatic adrenal carcinoma beyond the first line: a case report and literature review].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot | 2017 |
Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, | 2018 |
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2018 |
Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemothera | 2018 |
Primary malignant tumors of the adrenal glands.
Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, | 2018 |
Update in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, | 2013 |
Practical treatment using mitotane for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2014 |
Rare adrenal tumors in children.
Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenal Hyperplasia, Congenital; Adrenalectomy; A | 2014 |
Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic | 2014 |
Diagnosis, treatment and outcome of adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hor | 2015 |
Adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents; Antineopla | 2015 |
Surgical management of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2015 |
Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2016 |
Letting post-marketing bridge the evidence gap: the case of orphan drugs.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineo | 2016 |
Update on adrenocortical carcinoma management and future directions.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Endocrinology; Humans; Immunotherapy; Medical On | 2017 |
Emerging drugs for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic | 2008 |
Adrenocortical cancer treatment.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Algorithms; Antineoplastic Combined Chemotherapy | 2009 |
Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adrenocortical Hyperfunction; Antineoplastic Age | 2009 |
[Mitotane in the treatment of adrenal carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan | 2010 |
Practical considerations in the evaluation and management of adrenocortical cancer.
Topics: Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Diagnostic | 2010 |
Androgen- and estrogen-secreting adrenal cancers.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Algorithms; Androgens; Anti | 2010 |
[Management of adrenocortical carcinomas in children].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Beckwith-Wiedem | 2011 |
Surgical resection of a virilizing adrenal mass with extensive tumor thrombus.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2011 |
Contemporary management of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2011 |
Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
Topics: Adrenocortical Carcinoma; Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Interactions; | 2011 |
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined C | 2011 |
Metronomic therapy concepts in the management of adrenocortical carcinoma.
Topics: Administration, Metronomic; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplast | 2011 |
Xenograft models for preclinical drug testing: implications for adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Humans | 2012 |
Targeted therapies for adrenocortical carcinoma: IGF and beyond.
Topics: Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Animals; Antibodies, Monoclonal; Antibodies, Mono | 2011 |
The next generation of therapies for adrenocortical cancers.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan | 2012 |
Development of mitotane lipid nanocarriers and enantiomers: two-in-one solution to efficiently treat adreno-cortical carcinoma.
Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Drug Carriers; Humans; Lipids; Mitotane; | 2012 |
Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Fatal Ou | 2013 |
[Diagnosis and treatment for adrenocortical carcinoma].
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2004 |
[Adrenocortical carcinoma and its treatment].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemother | 2004 |
[Recurrent operations on the adrenal glands].
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Anti | 2005 |
Mitotane for adrenocortical carcinoma treatment.
Topics: Adrenocortical Carcinoma; Humans; Mitotane | 2005 |
Adrenocortical carcinoma.
Topics: Activins; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, | 2006 |
[Adrenocortical carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Combined Modality Therapy; Cytodi | 2006 |
Adrenocortical carcinoma.
Topics: Academic Medical Centers; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combine | 2007 |
[Adrenocortical carcinoma. Diagnostic work-up and treatment].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2008 |
Adjunctive treatment of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemother | 2008 |
Bilateral primary adrenal non-Hodgkin's lymphoma and primary adrenocortical carcinoma--review of the literature preoperative differentiation of adrenal tumors.
Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged, 80 | 2008 |
Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature.
Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Age Factors; | 1993 |
Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 1998 |
Cytotoxic treatment of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Cisplatin; Doxorubicin; E | 2001 |
[Adrenocortical carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Age Factors; Combined Modality Th | 2001 |
20 trials available for mitotane and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined | 2021 |
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2022 |
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2023 |
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Disease-Free Survival; Humans; Mitotane | 2023 |
Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineoplastic | 2021 |
Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Ho | 2013 |
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, | 2014 |
CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2014 |
Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Case-Control St | 2014 |
Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, | 2010 |
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activat | 2011 |
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activat | 2011 |
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activat | 2011 |
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activat | 2011 |
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Bl | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Combination chemotherapy in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap | 2012 |
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplast | 2012 |
No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; El | 2012 |
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinom | 2013 |
Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Ch | 2006 |
Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplasti | 1998 |
Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined | 2000 |
[Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe | 2001 |
174 other studies available for mitotane and Adrenocortical Carcinoma
| Article | Year |
|---|---|
The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.
Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Caspase 3; Caspase 7; Cell Line, Tumor; C | 2013 |
Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot | 2021 |
Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; In Vitro Oocyte Maturation Techn | 2022 |
Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aminopyridines; Antineoplastic Agents; Antineopl | 2022 |
Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Biomarkers; Hum | 2022 |
Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Hydroco | 2022 |
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Male; M | 2022 |
Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan | 2022 |
Successful administration of mitotane (O, p'-DDD) in pediatric oncology.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Child; Child, Preschool; Drug Monitoring; Female | 2022 |
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Genomics; Humans; Mitotane | 2022 |
Massive adrenocortical carcinoma presenting as peripheral edema: a case report.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Edema; Humans; Hydrocortisone; Male; Mitot | 2022 |
[A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot | 2022 |
Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumo | 2022 |
Key factors for effective mitotane therapy in children with adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Child; Female; | 2022 |
Long-term complete remission of metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Combined | 2023 |
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Apoptosis; Aurora Kinase A; CDC2 Protei | 2022 |
Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Androgens; Antineoplastic Agents, Hormonal; Fema | 2022 |
Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic | 2023 |
Targeting of a New Node in Lipid Metabolism as a Potential Treatment Strategy for ACC.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Lipid Droplets; Lipid Metabolism; Lipoly | 2023 |
The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan | 2023 |
Favourable prognosis in metastatic adrenal carcinoma: An unexpected outcome.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Male; Middle Aged; Mitotane; Prognosis | 2022 |
[Morphological predictors of the efficacy of mitotane therapy in adrenocortical cancer].
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2023 |
Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Inflammation; Lymphocytes; Middl | 2023 |
Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Mitotane; Neoplasm Recurrence, L | 2023 |
New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study.
Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Cohort Studies; Female; | 2023 |
Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Androgens; Humans; Hypogonadism; Longitudinal St | 2023 |
[Adrenocortical carcinoma in women of reproductive age].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Female; | 2023 |
[A Case of Aldosterone-Producing Adrenocortical Carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aldosterone; Humans; Male; Middle Aged; Mitotane | 2023 |
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; DNA, Bacterial; Humans; Mitotane | 2023 |
Two-dimensional chromatography for enantiomeric analysis of mitotane and its metabolite o,p'-DDA in patients with adrenocortical carcinoma indicates enantioselective metabolism.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Chromatography, High Pressure Liquid; Humans; Mi | 2023 |
Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Carboplatin; Etoposide; Humans; Male; Mit | 2023 |
Adrenocortical carcinoma mimicking pheochromocytoma on iodine 123-labeled metaiodobenzylguanidine scintigraphy.
Topics: Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Four-Dime | 2019 |
The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Ce | 2020 |
A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Cytotoxins; Drug Carriers; Hep G2 Cells; Humans; | 2020 |
Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis.
Topics: 3T3 Cells; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Apoptosis; Ferroptosis; HEK2 | 2019 |
Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Drug Monitoring | 2020 |
[A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Antineoplastic Agents, Hormonal; Follow-Up | 2019 |
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Apoptosis; Cell Line, Tumor; Cell Survival; Fema | 2020 |
Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC.
Topics: Adrenocortical Carcinoma; Apoptosis; Female; Humans; Liver X Receptors; Middle Aged; Mitotane; Trans | 2020 |
Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Amenorrhea; Antineoplastic Agents, Hormon | 2020 |
Mitotane liposomes for potential treatment of adrenal cortical carcinoma:
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Biological Availability; Chemistry, Pha | 2020 |
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineopla | 2020 |
Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Choles | 2020 |
Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Liver-S | 2021 |
Extra-adrenal, non-functional adrenocortical carcinoma presenting with acute abdomen: a case report.
Topics: Abdomen, Acute; Adolescent; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormona | 2020 |
Ectopic adrenocortical carcinoma of the ovary: An unexpected outcome.
Topics: ACTH Syndrome, Ectopic; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Ag | 2020 |
Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Denmark; Humans | 2021 |
A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Asian People; D | 2020 |
Predicitve Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged | 2021 |
A rare case of right shoulder pain.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Fatal Ou | 2021 |
In vitro cytotoxic effect of a chitin-like polysaccharide produced by Mortierella alpina on adrenocortical carcinoma cells H295R, and its use as mitotane adjuvant.
Topics: Adrenocortical Carcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Chitin; Chlorocebus aethiop | 2021 |
Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot | 2021 |
Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; An | 2021 |
Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Japan; | 2021 |
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 | 2017 |
The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Topics: Adrenal Cortex Neoplasms; Adrenal Insufficiency; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and | 2017 |
Long-Term Survival in a Patient With Metastatic DDR2-Positive Adrenal Cortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Carboplatin; Combined Modality Th | 2017 |
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.
Topics: Adipose Tissue; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Ho | 2017 |
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; An | 2018 |
Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors.
Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Moda | 2018 |
High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Brain Di | 2018 |
Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe | 2017 |
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic A | 2018 |
The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Caspases; Cell Line, Tumor; Cell Proliferation; | 2018 |
Prognostic factors in adrenocortical carcinoma: data from a large Polish series.
Topics: Adrenocortical Carcinoma; Adult; Aged; Female; Humans; Male; Middle Aged; Mitotane; Mitotic Index; P | 2018 |
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Hum | 2018 |
Long-term survival in recurrent adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Adult; Antineoplastic Combined C | 2019 |
Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, | 2018 |
Mitotane-induced dyspnoea: an unusual side effect.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Antineoplastic Agents, Hormonal; Diagnosis | 2018 |
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2018 |
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2018 |
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2018 |
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2018 |
Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane.
Topics: Adenine; Adrenocortical Carcinoma; Cell Line; Computer Simulation; Drug Synergism; Gene Expression R | 2019 |
In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Apoptosis; beta | 2019 |
A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Dose-Res | 2019 |
Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, | 2019 |
A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcino | 2019 |
Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adrenocorticotropic Hormone; Adult; Antineoplast | 2019 |
National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Antineoplastic Agents; Anti | 2019 |
Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence.
Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineo | 2013 |
Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; | 2013 |
Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplas | 2013 |
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineo | 2013 |
Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Ag | 2013 |
Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, | 2014 |
Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 | 2014 |
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Albumins; Animals; Antineoplastic Combined Chemo | 2014 |
Therapy of adrenocortical cancer with o,p' DDD in two children.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Dichlorodiphenyldichloroe | 1963 |
Hair cortisol measurement in mitotane-treated adrenocortical cancer patients.
Topics: Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Fem | 2014 |
Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; | 2014 |
Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Ar | 2015 |
The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Apoptosis; Cell Line, Tumor; Cel | 2014 |
Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antibiotics, Antineoplastic; Antineoplastic Agen | 2014 |
Metastatic adrenocortical carcinoma with a prolonged response to mitotane.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2014 |
Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; C | 2014 |
Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease.
Topics: Adolescent; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Biomarkers; Female; Go | 2015 |
Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Antineoplas | 2015 |
Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2015 |
A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2015 |
Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Cell | 2015 |
Sunitinib monotherapy instead of mitotane combination therapy for the treatment of refractory adrenocortical carcinoma.
Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Humans; Indo | 2015 |
Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Female; Follow- | 2016 |
Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumo | 2016 |
Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Ce | 2016 |
Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Topics: Adaptor Proteins, Signal Transducing; Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carci | 2016 |
Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agent | 2016 |
Adrenocortical carcinoma: Retrospective analysis of the last 22 years.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Chemothe | 2016 |
Discussion.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Female; Humans; | 2016 |
Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; beta Catenin; C | 2016 |
Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti | 2016 |
FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria.
Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Calcium; DNA-Binding Proteins; | 2016 |
Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Animals; Antineoplastic Combined Ch | 2016 |
Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti | 2016 |
[Adjuvant mitotane treatment after adrenalectomy is not beneficial for adrenocortical carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Chemotherapy, Adjuvant; Combined | 2016 |
Multi-Target Approach to Metastatic Adrenal Cell Carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combin | 2016 |
Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Bortezomib; Cel | 2016 |
Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic | 2016 |
Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Biomarkers, Tumor; Cell Line, Tumor; Ci | 2016 |
Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient.
Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Carboplatin; Drug Therapy, Combination; E | 2017 |
Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; CDC2 Protein Ki | 2008 |
Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic A | 2008 |
Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies.
Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease | 2008 |
Successful treatment of adrenocortical carcinoma with pulmonary metastasis in a child: report of a case.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2008 |
Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Cell Line, Tumor; Cell Proliferation; F | 2009 |
A patient with ectopic cortisol production derived from malignant testicular masses.
Topics: Adrenal Rest Tumor; Adrenocortical Carcinoma; Adrenocorticotropic Hormone; Aged; Cushing Syndrome; H | 2008 |
Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adrenocorticotropic Hormone; Adult; Antineoplast | 2010 |
How is adrenocortical cancer being managed in the UK?
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2009 |
Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy.
Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free S | 2009 |
Management of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Catecholamines; | 2009 |
Development of microemulsion of mitotane for improvement of oral bioavailability.
Topics: Administration, Oral; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Biological | 2010 |
The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Algorithms; Anti | 2010 |
Mitotane serum level analysis; good agreement between two different assays.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Blood Chemical | 2010 |
Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Combined Modali | 2010 |
Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot | 2010 |
Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Cell Proliferation; Cyclin B; Cyclin-Dependent K | 2010 |
Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti | 2010 |
What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Ki-67 Antigen; Mitotane; Neoplasm Recurr | 2010 |
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic A | 2011 |
Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
Topics: Abortion, Induced; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, | 2011 |
Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure.
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2011 |
Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Antineoplastic Combined Chemotherapy Proto | 2011 |
[Adrenocortical carcinomas: therapeutic advances in 2011].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined C | 2011 |
Simultaneous analysis of mitotane and its main metabolites in human blood and urine samples by SPE-HPLC technique.
Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hor | 2012 |
Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumo | 2012 |
A fly in the ointment: reassessing mitotane's role in the treatment of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Biomarkers, Pharmacological; Clinical Trials as | 2012 |
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; A | 2012 |
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; A | 2012 |
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; A | 2012 |
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; A | 2012 |
ADRENOCORTICAL CARCINOMA TREATED WITH O,P' -DDD.
Topics: Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Child; Cushing Syndrome; D | 1965 |
The effect of o,p'-DDD therapy on plasma cholesterol in adrenal carcinoma.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Cholesterol; Dichlorodiphenyldich | 1961 |
[Features of clinical presentation of malignant adrenocortical tumor cortex metabolism over time].
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormon | 2003 |
[Histoculture drug response assay guided concurrent chemoradiotherapy for lung metastasis from adrenocortical carcinoma--a case report].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[Practical use of o,p'DDD in adrenocortical carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Female; | 2005 |
Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.
Topics: Adjuvants, Immunologic; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antigens, Neoplas | 2006 |
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe | 2006 |
[Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; | 2006 |
Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Combined Modali | 2008 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane treatment for adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane therapy of adrenal cancer - use and controversy.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Tailored hormonal therapy in secretory adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang | 2007 |
Adjuvant mitotane in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Adjuvant mitotane in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A | 2007 |
Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Biomarkers, Tum | 2008 |
Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Car | 1995 |
[Bilateral gynecomastia revealing malignant feminizing adrenocortical carcinoma].
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Diagnosis, Differential; Feminization; Gynecomas | 1994 |
Mitotane in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Chemotherapy, Adjuvant; Humans; Mitotane | 1994 |
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Child; Child, Preschool | 1994 |
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Two years later.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Chemotherapy, Adjuvant; Female; Follow-Up | 1996 |
Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Dehydroepiandro | 1999 |
Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti | 2001 |
Hyperadrenocorticism associated with excessive sex hormone production by an adrenocortical tumor in two dogs.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adrenocortical Hyperfunction; Adr | 2001 |
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplasti | 2002 |